var title_f3_48_3840="Venous insufficiency PI";
var content_f3_48_3840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic venous insufficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 436px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bickley LS, Szilagyi PG. Bates' Guide to Physical Examination and History Taking, 8th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_48_3840=[""].join("\n");
var outline_f3_48_3840=null;
var title_f3_48_3841="Hip PI";
var content_f3_48_3841=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 596px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJUAZADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAzrnUPL1KK0TBZhk1o159pmoNqHxMuI1bMcCt+nH8zXoNZ05892XOPLZBRRRWhAUUUUAFFFFABRRXi+o/Gy6sIvFeoSeGYn0Xw5qv8AZl3Mmpfv2/ebBIkRiCkZxxvB5/GgD2iiuO1L4meEdNvmtL3VxFKhiWVvIlaOBpBlFlkClIyw6ByK5zTfirBa+MvGmn+KpbWx0vSL6zsbOeKCVmd50c4kI3AcpwcKB3oA9UorzX4i/Eq00fStbTQNW0mPVtGnt4r06lbXT28Pmn5VJhQksR0C5x3xXSt440H+359FguLu71C3dI7hLOwuLlIGf7okkjRkQ8H7xGMc4oA6WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKbK4jjd2OFUEn8KdWZ4om+z+GtVmHVLWVh9dhpN2VxpXdjzf4Nlr7xDrOoP12AZ/32J/9lr1uvMvgZBt0rU5/786p/wB8rn/2avTawwq/dI2xD/eMKKKK6DAKKKKACiiigAryLwn8H7aHxB4rv/FqQajBqWtPqdnbR3c5hCliy+dD8sbOM9w31r12igDwzWvg5eza94slWGw1nSteuRd/Z73Vr2yWCXOTvigBWYBsEZKkYHPerd18ILy/i+JtveT2HkeJEtTp2x3JgkgRtpkyvA37ehY4zXtFMmRpIXRHMbMpAdQCVPqM0AeEXPwb8QXXwh1fQ7vUtOuPFesamNSvbx5JPJYhwQA2zd91f7o5J7c1q6/8MNYvPiCmv+HjbeG3e+Se8vLTVp3a8iU8h7bylQMwxn5yOO+Sa9E8Aanc6r4SsJtRIbUog1reEDGbiJjFKcdgXRiB6EV0NABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc98QX2eC9XI/54EfmQP610Nc98QlL+CtXA6+ST+RBqKnwP0Lp/EjnvggP+KVuz3N63/oCV6FXnvwRI/wCEVux3+2v/AOgJXoVRh/4USq/8RhRRRWxkFFFFABRSEhQSSAB1JrKufEOl25Ia6V2HaMF/5cVMpxj8TsVGLlsjWorB/wCEq03/AKb/APfs1LH4m0putwyn/ajYf0qFXpP7SKdGovss2aKzk1vTHxi9gH+82P51bhu7eb/U3EUn+64NWpxezJcZLdHLeG8aZ458TaTysV35Wr247fOPKlA+jxBz7y119cj4xzp3iTwtrakBFuW0u4PT91cgBf8AyMkA/wCBGuuqiQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACs3xLB9q8O6pABkyWsij6lTWlSOodGVhkEYIpNXVhp2dzzL4F3G7TdUt/wC5Mkn/AH0pH/stenV5B8GWNp4l1iwbr5fI90fH/s1ev1hhXekjbEq1RhRRRXQYBTZHWNGd2CooySegFOrnvGN0VtYbOM4a4b5sf3R1/XH61nVqKnBzfQunDnkooydTvZtalKoWjsgflTON/uf8KZHZQRDkCrMMYhtxx2rMubkhzzXz86kqkuaTPVhFRXLHYumCAjoKiezibpiqIuj609bk+tQXZkrach6YpjaYp6gU9Lo+tTpcg96AuzD8T6Jd6l4cv7G1uZklkiJh/eEBZV+aNvwcKfwq/wCGfE2rajoWn6lFMHjuoEm8uVBlcgEqe+QePwrTWYGub8FMtnda7orHiyvWmhB/54z/AL0fgHaVR/uVtCrOMfdexlKMW9UddD4onTi7sc/7UTf0P+NaVn4j0+4wHkaBz/DMNv69P1rHMaN1AqJ7SNuwraGOqx31M5Yem/I7RHV1DIwZT0IOQadXCxwSWrbrSWSFuvyNgH6joaux+Ib21P8ApMSXEfcr8rf4H9K7KePhL4tDnlhJL4Xc62isvTddsL8hYptkp/5ZyfK3/wBf8K1K7YzjNXi7nNKLi7NBRRRVCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8e8M/wDEv+Mt9B0E0k6gexG8fyr2GvHtc/0H41WkvQTSw/8AjyBK9hrmw2nNHs2dFfXlfkFFFFdJzhXF61IZ/E0iZyIkVR7cZ/rXaVxGpKY/FN4T/EFI/wC+RXDmD/dfM6sJ8b9Ca/VjaNszkDIxXMSyE8nrXYlQ0XHXFclrNu1rMXAPlufyNeNax6EGVxIc1IslUi/epI5M0GhdDmnpIR3qshp4NArF6OYjvWHey/YPHelXg4i1K3k0+U/9NEzLF+nnj6sK0laqGu6cdVtII0l8maC5huYpdu7ayOGPHuAyn2Y1UXZ6kSV1odWkvvUySZrLilqyj1INGgCDTHiVh0qBZMVMkmaBGfd6ckmTt59RS2Wo6lpjgLIZ4B1jlOePY9q1AQajkhDCqhUlB3i7CaUlaSubmla1aajhEby5+8T8H8PWtOvPrqxBIZcqwOQw4IrU0nxDLbYg1Tc6Zws4HI/3h/WvUoY5S92pocdXC21gdbRTUdZEV0YMjDIIOQRTq9E4wooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8d+KLfZviLo9wONscEn5St/hXsVeOfG9dmuaXN0zARn6Nn+tewxNvjVv7wBrlo/wASaOir8EGOooorqOcK5DxbEYNUtrlfuyJsP1B/+v8ApXX1leJrJr3SnEYzLEfMQDvjqPyzXPiqftKTSNqE+SabMu1k3xCmXlslxC0ci5BFZukXYEojJ4YZFbwAce9eElc9F+6zhNS06SyY8Fos8H0qknXINegXFuJFKsuRXN6nou0mS3+U/wB3saRpGdzMRuKlRs8VSJKsVYYYdRUkb80iy6KeKhRsipAaBEqNirEctVAaeDQI0FepVeqEb1OrUCsX45KsK+azkerEb0EtFtlDCqVzbBgeKto9PIyKQjL0/U7nRpccy2ROWj7p6lf8K7i1uIru3Se3cPE4yCK5C4gDg8VFo94+j3hzuNpIcSKP4f8AaArvwmLcHyT2/Iwr0FNc0dzuaKRWV1DKQVIyCO4pa9k84KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8h+Ow/0vSD38uX+a16xY82VuT/zzX+VeS/HR92o6TGOoic/mR/hXrdquy2hU9VQD9K5aX8afyOip/Ch8yWiiiuo5wooooA898UWT6Tqy3EQP2aY7lx0Vu4/rWvY3SzRI6nqK6LULKDULR7e5XdG35g+o964S703UNAnLKrT2OeJFHQf7Q7V4+Lw0oS54bHo0ayqR5ZbnTqVao7iNStZNtq8MkeQ3zelXEu45EDBuK5HNNamnI0zm/EljtUzxDDLyfcVixHcoYd66jWblDbyDqMEVy9ujLD8wxWZ0R2LEb1YVqoq3NWEbigZaFOBqGNqloESoeanU1VU1MjUCLCtU6NVYVIpoEXo3qwjVQRqtRNmgllhhkVUuIQ4Iq2p4pJF4pCLfhW5PlyWUjEtF8yZ/uHt+B/mK364lZzY6paXI4Td5cn+63H/ANf8K7avcwVXnp2e6PPxMOWd+4UUUV2HOFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRQaKACiiigAooooAKKKKAPHPimv2/4haTZKc5jhjI9C0jf0Ir2OvHrr/iZfG6Neqwyrj22R7v5ivYa5sPrKcvM6K2kYryCiiiuk5wooooAKCMjB6UUUAZN54f026bc1uI5P70Xyn9OK5bxLoc2lItxZTSvbZw4bBKn1+ld/TJoknheKVQ0bjawPcVzVsNConpZm9OvKD30PONPsftC75HLnrzUWpWnlngYrREL6Nqb2cuTEx3RN/eX/Gp9ZiD24kXtXhyg4tp7o9NTvZrZnHsu1qkQ1NcR96rrxUmhMrVOrcVXUelSKaAJs09G5qEGnr1oEXozkU8GoYTxUuaBEyNVqE1RQ1cgoJZfj6U8jimRjipKRBm6qiG1k8wgLjqa6rRbkXelWs4bcWjG4+44P61yV1bDUr9Y3P+iwcuP77elS29zNpdwXtwPJJ+eLsR7ehrswldUZe9szOvS9pGy3R2tFU9M1G31GHzLduR95Dwyn3FXK9uMlJXR5rTTswooopiCiiigAooooAKKKKACiiigAooooAKKKDQAGigUUAFFFFABRRRQAUUVDeTC2s5526RRs5/AZoA8k+H/wDxMPilq151CGeRT9XCj9DXsNeSfA2EyXWsXb8ttjTP1LE/yFet1zYT+Hfub4n47dgooorpMAooooAKKKKACiiigDK8Q6aNQsTtH+kRfPGff0/Guftx9rtdh4OK7WuV1mL+zdTWZRi3uDz6K/8A9evNx1G69ovmdmFqfYZz2qWpg6jj1rJZcHiu0u40uYiCM5Fcjdwm3maNvXivKPQiyJTUnaogMGpo+aCgFSpQEzT1Q0CJEOKnU5qFVNWI0oEx6Dmr1utQQx81ehTAoJbJ0HFQahcfZrZnUZc/Ki+rHpVgdKp3CibUbaM9EDSn8OB/Oglbk1lb/ZbZI2bdIfmdvVj1p0sSuOalooFcymt5rWYT2btHKOhHf2PqK17HxKqgR6nGYn/56ICVP9RTCAetRSQI/VRW1HETo/CyZ041PiOlt7mC5TdbzRyr6owNQatdmztQ64DO4QE9Bnv+lcde2UKAuvykdxxWdpzTTXrl5ZXgUYAZiRu/H2/nXY8wbi1azMFhFe99DrXaaUgtcSnPo+0fkKAko6Szf9/WqnFvjUbW+X0PIqwly3G6P/vk1ye05tW2bcltkSD7R/z3m/7+Glzcf895v+/hqM3SZ5Ei/hSm7ix95/8AvmqU3/N+JPL5EgEx6zT/APfw09YyerOfqxNV/tkf8IkP4U5bhm4VOPc1Sl3Ymn2LiRqvPGauW8uHCZyD69qy1Lt94/gKsxLxjpXZRlZ6GFSN9zWJA6kUm4duap2/oetW16V3J3OZqwuaKKKoQUtJS0AFFFFABRRRQAVheObj7N4P1eTOP9GdB9WG0fzrdri/i9ceR4JuEBwZ5Y4//Ht3/stZ1XaDfkXTV5pGb8EIQvhy+mxy90V/AIv+Jr0auN+Elv5Hgi1fGDNJJIf++iv8lFdlU4dWpxKrO9RhRRRWxkeR33xYGl/Ejxp4f1q80TT7LSbKKfT3uZfKknleJXKEs4Dct0UA4rH8K/EzVvEOn/C/UdQ1E6bPr13eQ3FnYaekkFz5cm1QzySb4gAM5XcSSemBXbwfD3yvHXjDxH/aef8AhIbKOz+z/Z/+PfZGE3bt3zZxnGB9awPDvwb/ALGsPAFt/bvnf8Ipc3Nxu+x7ftXnOW243nZjOM/Nn2oAt6B8bPD+sLokw03WrOw1i8bT7W8uoohEbgHGxtsjMMnGDtxz14OPUa+fPhV8H9bHh/wxD4zmjsbfQ9Tl1KPTI4kkeWXdlGeZZGXbwPlCg9cn0+g6ACiiigArM8SWou9GuF/iRfMU+hHNadIwDAgjIPBFTOPNFxfUcZcrTRyemES2y89hWd4hsfMhLr95eamz/ZGpyWUufLzuiY91PT/CtOSNbiHrkEV884NNxe6PWUvtLY4KNiDtcYNWUGDWtq2mIIt8Ywy1St4i6A1mbXuhI6sIM0ghIqzDCaBNiRxZqzHDUkceKsIlBLY2KPFTqMU0sFFQSXKr3pElrNUom3axKc/chA/M/wD1qhe9Ud6oR3wGpTn/AKZr/M0xqJ0eaMisT+0h60jamPWgOVm5uFIWGKwTqg9ab/anvQHKy7dpJOxX7qetOtbVYwFUAKKz/wC0we9PXUs96B2ZurgDFGVrFGoZ70HUPegXKbDBT1pNqGsY6j703+0vegOVm6qoKnjK1zY1PnrViHUc96uBMos6NAD0qxGKxra93Y5rRgn3Yr0KJyzRooKnHSqsT5qwrV3wZyyRJRSClzWhIUtJS0CCiiimAUUUUAFeb/HCcLoFhBn5pLnf+CqR/wCzCvSK8i+N0rT6ro9in3tjNj3ZgB/6DXPinakzbDq9RHofgq3+y+EtIiIwRbIxHuRk/qa2qjt4lggjiX7sahR9AMVJW8VZJGUndthXBfHWR4PhR4imEFncxR2++W3u0kKTICMrmORGUnjkNx6Gu9rl/iR4avPF/hW70K01GDT4L1fKuJJLUzsYz2TEiBW9zuHtTEeVaN8R9c/ssaX4YstHsoNA8J2urTLdRzSrLm3RxDF+8BRQpxvYucjnPWqEfj5L7xyfFNjollFqL+ApdVSaZ5mdWR3PkkBwhj3L12hj6jpXqs3wv8K3NjYW97YyzPaafHphmS5lgee3QACOXy2XzF4Hytke1X7rwD4Zub17uXSkEz6W2iny5ZEUWZzmIKrBQOTyBketAHl3h34qeKNWv/CdjeR6NGPE+j3N3FLBbyg2k0aSEEgynevyDgFTz14yei/Zlv8AW9V+FGmahr2qnUjOZfKeZXa4XbNIp8yVnbzOgxhV2gY5611unfD7wvp15od1Z6WI59EgkttPYzyt5MbghlwWIbIY8tk81c8JeEdF8I29xb+HrWW0tZn8w2/2mWSJDkk7EdiseSxyFAzx6CgCxo3iHTdXvL6ztJyL6ykMdxayoY5Y+cBtjYOxuqsOCOhrWrD8S+GNP1/yJp/NttRtsm11C1fy7i3J67X7g91IKnuDWJH4k1Lwu623jhY2schY9et02wHsBcJz5Df7XMZ9VyFoA7eimo6yIrxsGRgCrKcgj1FOoA5/xbaB4Yb1Vy0DYbj+A/4H+tQWc6mMYxj2rpZEWSNkkUMjAgg9xXA6mJNG1N7ZCZISA6eoU9v0rysdScZe1id2GnzLkZr3e1kasq3iDbgPWkN1JLHkKwH0q5p6YQk9zXmtnWlZDBDzU0cWB0qztHpQFxQK5GEpJGCCpTwKy9Sm2I1IFqV7/UBGDg1zt5rKqxBkGfTNZXiLUzG2xT8xrnk3yN5kjE5pm6ikdM+rls4NRwakftb88vHgfUH/AOvWKp9BTyHGyRB8yHOPX2oGbiXjkcnFKbtvWs9ZRIgdPutSjJpgXvtTHvSfaW9arKpNPEZpASvepCheZ9qCsq48ZWEDFVDOR6c0ataGcYY5UdF96821SGW3upAQRk00hHqGn+L7S6cA7oweMntXQCfIBDZBGQc15F4YtpJZSzKfLxzmvRNKkeOwiDqxA4B9qGgsbBlJqNpD61F5yY5OKY08f94UgsTCRs9auWsgALSPtUdTWaJY89ah1NnktdseQCQCfatIkyRsL4lgSQpbRmTHBYniuj0jVluQAVKNXmUNrJBPgg7Cciu28OxNkMRxXfSOOojvLZ84q9Gay7I4UCtKOu6BxyLApaatOrVGYU6mGn0xBRRRQAUUUUAFePeL/wDiZfF/TrXqsLwIR7D5z+hr2GvHvDP/ABNPjHfXP3lgkmYH2UeWD+ormxOvLHuzooac0uyPYaKKK6TnCiiigAooooAKKKKACmuiyIySKGRgQysMgj0NOooA4iTw3qXhd2ufA7RtY5LSaDcPtgPcm3fnyG/2eYz6LktW34a8T6fr/nwwebbajbYF1p90nl3FuT03J3B7MCVPYmtysPxL4Y0/X/Imn8221G2ybXULV/LuLcnrtfuD3Ugqe4NAG5XHeJtp8SQhv+eI/wDQjUMfiTUvC7rbeOFjaxyFi163TbAewFwnPkN/tcxn1XhaXWWW68Rl42DIqIAynIII3cfnXFj3+6+Z04T4/kXLhFFqdgHSotOYGLb/ABDtV9IS8fC5FItp5bbiuDXlezb1sdnOthFXNOMfFSqtSbeKuNIhzKEgwDmsPVuEc+grpZo8isfUbffG646gis5w5TWErmH4e8B2mu2n9parNcDzWPlxxMFwoOMnIPpWldfDDTDHizvLyGQdC5V1/LA/nW94JuEbR0tGYCe2LIyd8ZJB+mDXQ169HD0pU07HFVr1IzaueG634bvtClxexh7cnC3EYyp+vofY1Q8sEZXmvfpo0miaOZFeNhhlYZBHuK8+8TeAiC114fO09WtXbg/7pPT6GuWvgXH3qeqOiji09JnnZ/0djn/VMcn/AGT61YXANOnikhmaC6ieGdfvRyLgiq8e6NxE33T9w/0rz2raM7Uy9GQasoBiqUeQeatI3FIBJ4d+cDrWPd6RHcON8Ib3rbzUioT6D6mgZk2mlxwrhgqr/dWtEYUAKAAOgqUx5HBU/Q1DIpHBoAGYHqBTcJ/dFRtmmnNAFlSuegq1FtcbW5FZoJq3bk5FaRIka1tbRnHAOK3rGMKAAMViWWTit2zPSu2icdQ27MYAFacXQVmWvatKLpXoQOORYFLSLS1qZiGn03FOpiCiiigAooooAiu51trWad/uRIXP0AzXkfwTha413Vb9+qxBCfd2z/7JXofjy6Fn4O1eUnG63aIfV/lH/oVcz8ErPyvDt3dEfNPcYHuqgf1Jrlqe9Wiu2p0Q0pSfc9EooorqOcKKKKACiiigAooooAKKKKACiimTSJDE0khwqjJNJu2rDcV0WRGSRQyMMMrDII9DXiGq6dqHhbU7y48GQ77Lzm3aPJ8sGAesDf8ALI/7PKH0XrXo2oanNdMVQlIv7o7/AFqgIS3UV5GKxaqe7HY9ChQcNZHnFz4v8dK6XNrDY2lsyq32e6tHkkX1BZZQM/Qce9d1ofjebUdKcJaRXGqxoP8AR2k8lXbjOCQ2B19f61Yns1ZeQDXH+INOOn3CahYjZIhyQO9YRxElobOlGR6Hoeq3WoSyxXuiX+mSxqGzO0Txvn+46O2fxAPtWwMHOCDg4OOxrI8M6muo6XDJkZKg1BeeE7OXWP7X02e50rU3dWnltGAW6AwNssZBR+BjcRuHYiuuHLLU5ZJx0N1xxVG6jyDUtzqNnBqVtp81wiXlyjyQxNwZAmN231IyOOuOafKuaxqx0LhI5+WB45hNCzRyr0dTg1p2XiKWFQmoRGT/AKaRjB/Ef4U+SHNVJrQN2rCnWqUX7rNpRhUXvHTWd/a3i5t5kc/3c4Yfh1q1XAyWTK25Dgjoe9WYNX1Kz+Ut5yDtJ8369a76eYJ6TRzTwj+wzodd0Gw1uHZfQ5kUfJKnDp9D/TpXnmqeA9YgLLZtDexZ+Q7tjj0yDx+tdtbeKLY4F3FJC3qPmH+Naltqtjc48m6iYnsWwfyPNbSjQxGt9fxJjKtQ0toeMXEFxaXclrfxeTdxgb0yD1Gc5FIGArqPivaCHU9N1GP/AJao0EhHfHK/zb8q4syn1ryq9L2c3E9GjU54KRJqV59lti6gs54UDua4TxFqmqxSKfPaMHnEfH612M/7wrkZweKhudBm1JMG2cjsSMVkaHn9trmqQkPHeyE+j8iu+0DxGNThEV0my5VQeOje4qonw9vCSywkL6EioptCvtNuYXa2kQKdpYDIwfpTA6Jph60CUGsoGbdhTuqwlvekZED/APfJoUW9kDkluzQVwTVqKVUBYngCsVVulbDgIfQir66ZqF3blYY3csPTAqkrPUl7DW1uaafZbtsjHGfWuk0aeZthMjE1nWPg27yHZQh7jNdRpuhTW20sN2Peu6icdU6DT2YqN3Na8XSsq0Rk4YEGtSHpXfA45FkU7Apq0/NaoyCikyaWmAUUUUAFFFFAHn3xru/J8MW9spwbi4GR6qoJ/ntrofAFn9h8G6VFjDNCJT9X+b+tcH8bpWn1PR7FPvBGfHuzAD/0E16xbQrBbxQp92NQg+gGK5qfvVpPtZHRPSlFdySiiiuk5woopk0qQxNJKwVFGST2obsA8nAyeBWTfeINOswd03mN/diG79elY+oatJqbGG3Bjt+h9X+vt7Vz+vWzW9k0i9RXnVsa1pTXzOynhk/jOrh8XWDsBJFcRKf4mUED8jXQxuskayRsGRgGVh0INeMWLy6nc29nBy7kLXsVjbi1soLcHd5SKmfXAxWmDr1Kt+bYnE0oU7cpPRRRXacoVgeJbwbobOM/Ozbnx2A6D/PpVzWtWi06MKPnuHHyIP5n2rk7YvJqIeZi0j5JJrz8biFGPs47s68NSbfO9jQih45qysQ9KkiWrKQkjpXmwpuR0ynYoSxDHSsDXLcSWsqY6qa6uaMgcisTUkyDSnDlZUJXOY+GtyytNasT+7kIA9q9MjNeT+DX+zeMLuE/dLA/rXqxOHNdNB2VzOutTO8TaFaeINMa0uzJGysJYLiE7ZbeUfdkjbsw/XkHIJFXFGFCM+91UZJxk+5A9cGpy2a5vVNJuB4v0jWtPVchHsr9S2N9uQXRvcpIBj2ketpO+hgtDcIpCgNSNimg1g0upqmyJoAahktQe1XNwqN5VXqaiUIjUpGbNYgjpWfJYqG+ZOPpW6bhO5FJmJ+eDWTiujNVNowJ7C2kiCzqXQHIUjIBqjLpdgBlbbNdYY4yPuiq13Goj+UCpaKjIydI0mAsH8hFweOK6GPT1A6AfhWdp9zGibCcOpwQa0v7RiUfM6j6mtKXJ9oio530H/YlA7Vk6vZgRNgA1efWLYcecmfrTJJUuoWKMGBHanUdNq0RQ507s5DSrKD7dIpjUYOeBXUJZ2wTHlgmsazTZqsnuK6JFyK9fBu9GJxYn+Izm76yj+1xKEG1nxgiuosbVAgAUAVi6iMXtv8A9dBW6JRDGCTgVyYtr2yv2NqN/Z6F1YF9KlWIDpWZHqcJON4q5FeRsOHH51dOcHsRKMkWQgqSMVCsgPQ5qxH0rsgYyHjpS0CitDMKWkzS0xsKKKKBBRRRQB4548b7X8WNKtzyqPbREexfcf8A0KvY68Zu/wDTPjcg6hLhP/HIwf5ivZq5cPrKb8zor6KK8gooorqOcDwOa4fxDqzahcGC3b/RUOOP4z6/StbxjqJt7MWsTYlm+9jqE/8Ar/41zFlEMAmvLx2I19nH5ndhaWnOzU0uEKFzVnVrVbi2aNhwwptsQAKtkhlwa41JONjZ3UrnJeELKLRvErz3z7YRGwjYgkBiR+XGa9H+32mwN9qg2nv5grmp7dW7A1SexQ/witaOLdGPLYmpRVV8zZ1M2u6bF1u42PonzfyrKv8AxG0g8vTYjk/8tJB0+g/xrMjsFU8KKuwWoXtVTx1Wei0FHD046vUpQ2ryyma4dpJW5LN1pzL5eow4+lagQKKzrgZ1KEDtzXG073ZsmbNuoNaEeAKz4GxVtHHrXfh5JI5aiuxbtQUzWDepkGtud8risu6GQazxLTd0XRujzgg6f4zil6LLx+PWvUxKJEjkHRhXnvi6ydoluYR+9hbeMd8Vt+E9div7MIW+YcYPUH0rnhOysb1I8yudTurN8SXlzY+HdUu7ARNeW9rLLCJQShdUJUMAQcZAzyPrVwNxTLl4hbym5KCAIfMLkBQuOc57YrZTMXEbp92L7T7W6UYWeJZQPQMAf61OTgVXsVtorG3SxES2ixqsIixsCADbtxxjGMUlxLtQnNRKQ4xuNurpYkJJ6VlNDrGprv0+EJB2kcgbvpn+dR6cjavriQnm3j+eT0IHb8TgV6AqhFCqAqgYAAwBW+Gw3tlzS2JrVfY6Lc8wu9I1W1zJfifYOrK25R+XStDS3TAw7E/WvQK5vXNADbrrTF8udeWiXhX+g7GqrYBxV6buFPFqXuz0Gg5HFDAMMGs7Tb5ZgUbKuvDKeoNaPWvOOhqxSuNPimOT1qr/AGNFnua2KKA5mZY0mFR93moLbNpfKqn93IdpFbZ6VkXS4uUPfcP50DTuQHC60R6rXQRjCVzlxka2vutdChxGK93B/wAJI83E/GZGsHbNA3pIv86k1eRmEcIP3utM1ojMP/XRf50695ukP+zXHjv4i9DowvwklnZoFG7k1qwWyjHFQ2aDArSiAqKI6jJbeML0FXF6VXjqdTXp0zjmOzQBmlApa2MwwKKKKACiiigAooooA8a0D9/8arlj/BcXH6Kwr2WvHPBw3/GDVD/dmuj/AOPEV7HXLhfhfqzoxG69ApHZURmYgKBkk9hS1j+K7r7LodwQcNIPLX8ev6ZrecuSLk+hjGPNJI4nUbxtQ1OWc52s3yg9l7Vbt+AKyrMc1r265xXzkpOTuz2LJKyLsRxirSMTVVBjFW4VoSuQyTBNKI81Io4p4wOtaKC6kOQxYh6U/AFI0mOlQvJVNxjsJJsdI4A4rLkdU1CNmPBBA+tTXE4UHmsq8l81OOo5rFu7NYo6BJMVOsvHWsqxn823Qk89DVkPVxqOJDhcuNJkdaqzNmmmSoZJKUpuQ4xsU79A8bAgEEVwF+r6HqgvLfPkOcOorvbqT5SK5rVrcXEEiMMgipTsao7LR75L6xjmjbIIzmofFVtd3/hjVrPTjGt7cWksMBkJCh2QhSSOcZIrm/hvMwtJ7dif3TkAe1bOq6tNF4k0XSbPYXufNuLncM7LeNcEj0JkeID23VUW09DOaRsWkKWlpBbRcRwosa/QDAqpqswSBue1WppNq1zupzvczrBCCzEgADuT0FTdtlRR0XgC1KWdxdMPmlfaPoP/AK5/SurqrpdoLHT7e2GMxoASO57n881ar6GjD2dNRPKqz55uQUUUVqZnK+KtLaJzqlkvzrzOg/iH976+tRWFytxArqa68gEYIyDXE3VqNI1loI8i2mHmR/7Pqv4f1FeTjsPy/vI/M78NV5lyM0aKQHIpa846ArNuVzcp/vj+daVZ83E6H0cfzoGihd8a5Hn+6RW/n92tYF4Cdai+hreA+QV7mC/h/M8/E/GY+rnMkX/XRf51Nc/8fSD0WotZwGi/31/nUk3N2v8AuiuTH/xF6G+F+E1bT7orQjqha/cFXo6zojqFhDirEPzDNU2OBWhGu1APQV6lLY45i0UUVsZhRRRQAUUUUAFFFFAHj3gf/krmsf8AXW6/9GV7DXjng47PjDqY/vT3Q/8AHia9jrmwvwv1Z0Yj4l6BXF+O7sPPBaKc7Bvce56fp/Ou0ryrUrk3eqXM2chpCR9M8fpWWPqctPlXUrCQvO/Ydaodw9K2IE5FUbJSQK2LePIFeMd7ZLBFmryxYXpSW6ACpZJAorphBJXZhKTbsiu528UwsTTZZQWphfC5rCT10NEglkCD3rNur3aTzim6hdCFSSeTWGXadsnpUlpFx5mmY/McVA7sowpxUM9wtumBy3pWe1xK5JPFOxSRuWN59nba5+Vq1hcgqCDkVxscxJ2tkirtvdPDwcsnpSBo6M3Q9agmvFHGazftKS/dbB9DxUb9eaAsWJbjcetU7mQeWSaazAHvWJ4k1m006wlluJ0iRR8zMcAf/X9qaV3ZBsavg2eK1Op3k8iQ2sQLvI5wqqASST6AV1Ok3dpqdtb6rbREfaIQUkkiKSeWeQDkZA74Nc1pPhm11DQbIaoszRNMl4bdt0ayEDKrKhAJAODtPdRnpiuo8zlqbsid2QardeXGcHk8Cr3gjTN5fUbhcnJEWf1b+n51jQWsmsaslshwg5dvRR1NejwRJBCkUShY0UKoHYCu7A0OaXtHsjnxVXkjyLdj6KKK9c84KKKKACsDxjEDZW82PnimGD7EEEfy/Kt+ue8ZS/uLS3X70ku78FH+JFYYq3spXNqF/aKxXhOY1qSo4RiMCpK+fPRCs+++Uk/jV4tgVm3z7sgck8CgaKt7xqUDeprY3/KKx9S4vLb6/wBK0kbKV7WAd6fzODFfGvQoa0c+V/10X+dSysBdL/uiq2rHDQAn+MGpbnIuIj2K1y4/+IvQ3wvwG3aHKir0dZdpJgCtKJgaypDqInxla0FO5QfWqKCrVufl2ntXq0XocVQlooorczCiiigAooooAKKKKAPGtG/0X41zKeA9xN/48jH+tey1414hBsfjPaSjgTXEBH0YBD/WvZa5cNpzR8zoxGvK/IranJ5OnXUgOCsTEH3xXltvHlq9N11S2jXoHXymP6V5zY4ZhXHmPxRRvg/hZq6fH04rZijKgcVW0+MDFanAFccKd1c2nKzGhgqVkapfiEcdTVq7mEasSelcbdzteajsU5UdaU530HCHU2LO5luJh/drUncRREnsKh022WKMcVV1qchSi96VrK493YyLl2ubgk/dFMlIgjJz83pU9uuB70k0G45btSSL8jLdd/zv37UwJvOAKmuDl9orX8NaS1/dhSCEXl29BRGLm+VbjlJRV2R6Rok162IYyR3PQD8a6y18JWyqDcyuzeicCuighjt4lihQIg6ACpK9elgYRV56s82pipSfu6GMvhrSwBut959WY1zvirTbfR5YbqK3zYyfu5FBOY27EfX+ld3VbUrOPULGa1mHySqV+h7H8K1q4WEoOMVZk068oyTk7o8z/sy11Hm3v3CHqFxkVYtfDeiW81vPPBHc3MEnmxPKAxR8EbhnocE1iG0mtLqRVJSeFyjY7kHFbFvcm4jw4w4614fM46HqSjc1pZ2eToAtV522QSv7HFNVsLzzUF+/+iuB0qQSOh8BWgW0nu3HzytsB9h/9f8AlXVVmeGY/K0GxGMbow//AH1z/WtOvocPDkpxR5NaXNNsKKKK2MgooooAK4u9nGpaxJMhzDF+7jPYgdT+J/TFXte1b7RustPfOeJZVPAH90H+f+cVbSJYIgvpXk47EKX7uPzO/DUnH35FlRhcUySUL3qtc3QXIBqlI+V3ysVT9TXnHUkWLi6+bbGCzegqB3WHEkzAuOQOwqK1F1qEhj06AlQcF+ij6mui07wvBEyy37m5l67TwgP07/j+Vb0cNOrstCJ1YU9znrS0utauibcBUiBO9s7c/wB3PrWkmmaqny/ZlPv5i4/nXXxosaBI1VVHACjAFOr2cPRVGHLc86tV9pK5xx8N310xe5kii2glVByc9qzJ5TG32a7Uw3Ef94df/re9eiVXvbK2vY/LuoUlXtuHI+h7VnicMq2qdmXQr+z0exxtnI4+8Mr6jmtm1kyBg5qlqHh64smM+kyNIg5MDnJ/A9/pTdOvEuOGHlzDgg8c1wqlKnK0jqc4zV4nQxHIqynHIqhbtng9avx9K9CjscVQmHIopopwrpMgooooAKKKKACiiigDyD4xo1j4p0fU0GDsGD7xvu/9mFeuxusiK6nKsMg+1ec/HC08zQbG6AyYbjZ9Ayn+qiuu8F3f27wppU5OWNuqsfdRtP6g1zU/drTj3szonrSi/ka8sYlieN+VcFT9DXlahtP1Ca2m4eJyp9/evV65Txt4cbVIvtlidt9EuNvaQen19KzxlB1I3juh4aqoSs9mZ9teqAMGrh1FAvLV5ot9eW0jLICrKcFWGCDVmW7uLkIyEjHBxXj3a0PRcEzptZ1LbGwB68CqOhwfvfMccnmobO1kuBH5uTit62thEARUj2NOIgR8VhX5MlyfQGtZXwMVnNHunJ96pu5CViOCPFNu/ljNX0jAFUdSwqGn0GtzAyTP7Zr1PwtaLa6RCcfPKPMY/Xp+leT3L7IpWHYV6V4J19NW0+OKRRHcxqAVHRgO4/wrrwDiqmu/Qwxak4abHS0UUV7J5oUUUUAef+MLP7Nr3nKMR3Khv+BDg/0/Os1IiGytdd46t/M0pJwPmgkBz7Hg/riuVSQbAa8LGQ5Kr89T1sPPmpryLC/dpkybomB9KI5M1bRA6muU12Og8IajHd6XHbkgXFqojdfYcA/TFb1eWSx3lreLcaeXhmXow6EehHcV0Nj4su0QLqNjvYdXhOM/gf8AGvWw+NhyqNTRnDWwsr80DsqK5g+LoSP3djdE/wC1tA/maik17ULkYt4YrdT3Pzt/QfpW8sZRj1MVhqj6HR317b2MJlupVjXtnqfoO9cxqGrXOqgxWwa3tTwxP33H9BVYWLTzeddyPNL/AHnOf/1VcVFjGFFefXxsqmkdEdVPDxhq9WRQQJAgVQBiormcIMZqS4l2KfWsp5A2ZJD8g6D1riOlK4+WRUTzpvujlV9at6TolzrLrc3paGy6qvRpB7eg9/8A9dX9E0H7QyXmpL8uQ0cJ/Qt/h+fpXV16WGwV/fqfcclfE292BFa28NrCsNvGscS9FUVLRRXqpW0RwbhRRRQAUUUUAFZGq6MlxL9pt8R3A5Po/wBff3rXoqZRUlZjjJxd0Y9luI2yArIvBBrSj6U6WFXO4cOO9InoetRGHKVKXMSCikFLWpAuaKSloAKKKKACiiigDlfifa/avBGpADLRhZR7bWBP6Zqj8Hbnz/BkcZOTBPJH+ZDf+zV0Xi2PzfC2sJjrZzY+uw1xHwMmzpWqQ9kmV/zXH/stcstK680dEdaL8mem0UUV1HOcf438Ox3cJvraMCdf9YAPvL6/hXJ6VaBSVde9etkZGDyDXAa1af2fqckajEbfOn0NeTjqHK/aR6noYWq2uRk1tCqgYFWXTC9Kr2LhsVoyR5SuFRurm7dmZvelRAcnvSyrtenRkVBQpXArG1hwFNbch+Sud1k5Bqr6BHc56+b/AEOX3rU0l5LOxtrq3YrInORWRec2kgq5a3oXSxEeopJ22LauewaPfLqOnQ3Kcbx8w9D3q7XOeAlYeHkLdGckfTiujr6GjJzpqTPGqRUZtIKKKK1IKeswfadKu4gu5mibaPfHH615kjkxjFes15jrtsdM1maB1xC53xHttPb8On4V5mY09FNHdgp7xIrcnPNa0B+Ws2JRtBFWoZMGvLO5l5SCeamSJX7VBH81W4Righgtsg7CpAioOAKduApjuvrSEI7+lVp7hY1OTzUV1c7eF6+tQ2FnPqUxNum/BwZG4RaqMXJ2ih6RV2V5JGlO58hey9zXReH9EIYXeoJ84/1cLDhfcj19u316XtK0SGycSynzrgfxEcL9B/WtevVw2C5Hz1NzirYnm92GwUUUV6JxhRRRQAUUUE4HNABRQCCMjpRQAUUUUAFIwz9aWigBBRSmkoAUUUlLQAUUUUAFFFFAFLW1DaNfqeht5B/46a80+BLc60v/AFxP/odek+IHEeg6k56LbSt+SmvOPgShEesv2JhH/of+NctT+PD5nRD+FL5Hq1FFFdRzhXP+MbPzbFblB88J5/3T/kV0FR3MQnt5Ym+7IpU/jWdan7SDiXTnySUjz/TpPmFdFGN8VcpAGguWjfhkYqfqK6nT23xYrwqW9melU7lC8XBqsjc1pX0dZXR6zkrMqLui23KVgaqnJroY+UrG1ZcE1JSOXukzbyj2zVnwb4fuNeuSWzHZxn55MfoPelkUMzof4gRXq3hqCK20CwjgQInkqSB6kZJ/OuvCUVWl72yM8RVdOOnUu2dtFZ2sdvAu2KNdqipqKK9tKysjym76hRRRTAKyfEWjQ6zZ+W52TJkxSf3T7+1a1FTKKmuWWxUZOLujyAvc6ZdSWl9GVkQ4PuPUe1XoblGwQw5rv9Z0Wz1aMC6j/eKMLIvDL+P9K4++8E30TE2VxFMnZX+Vv8K8etgpwfuao9OnioTXvaMltpRjrVrzgBWRDoGvxtgW3H/XRcfzrUtvDeqyD9/cQwj2yx/w/WsFhqsnZRZUqlNa8yGy3OAeapNdGSQJHukkPREGSa37bwlAGDXl1NOf7q/Ip/rW9Z2NrZrttYI4h3Kjk/U1008vm/jdjGWKhH4dTmdO8PTXREmokwxdolPzN9T2rqreGO3hSKFAkaDCqO1SUV6VKhCkrRRxVKsqj1CiiitjMKKKKACiiigArh/HHik2WpQaPYfPeS7S+P4c9B9a6vWtRh0nSrq/uD+7gQuR6nsPqTgfjXl3wr0+bXPEF94h1H95sc7Sehkbk4/3Rj8xXPWm7qnHd/kbUoqznLZHq2nRNDZxJISXCjcferFFFdC0MQooooAKKKKACiiigBKWiigAooooAKKKKAMrxadvhXWT6WU3/oBrh/gYmNK1N/WdR+S//XrtfGPHhLWv+vKb/wBANcf8Dh/xINQP/T1/7Itc0/48fRnRH+DI9IooorpOcKKKKAOB8SW/2XXZCBhZcSD8ev65rS0eTIAqbxrbAw29yB8yNsP0PP8AT9aztJk5FeHXj7Osz06b56SNe7TK1hTja5ropBujrDvkwxrOstbjpvoOt2yKo6qmRmrFs3NF+uYzWBqtzlJRiYH3r1Xw6/maJZkdowv5cV5TdHZMfrXpPgqbzdERc8xsV/r/AFrvy+VqjXkYYxXgmb1FFFeweaFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAebfG7UvI0az09GIa5l8xgO6oOh/FgfwrqvAukjRvC1jalcSlPNl/325P5dPwrzzx8P7Z+KGm6aeY4zDEy+xO5v0NexVy0veqyn20Oip7tOMe+oUUUV1HOFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAY3jT/AJFHWf8Arzl/9BNcl8Dv+Rdv/wDr7P8A6Atdb40/5FHWf+vOX/0E1yXwO/5F2/8A+vs/+gLXNP8Ajx9Doj/BfqejUUUV0nOFFFFAFDXoBcaRcrjJCFx9RzXG6Y+GFegMoZSpGQRgivOghtb+WE/wOV/I15WYw1jI7sJK6cTqoTuirN1BOpq3YPujApL1Mg1zP3oGi0kY0PD1NcjMdMK4epX5jrmZscfqy7Zs+9dl8O58x3EJPYMP5f1FcvrcfU1qfDufbqZQ/wAaFf5H+ldGFly1Yk11zU2ej0UUV755IUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRSMQqkngAZNAHj/AId/4mfxmvZz8wgkmP4KPLH9K9hrxv4Obrrxfqt4f4oHJ+rSKf6GvZK5sJrBy7tnRidJJdkFFFFdJzhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGP4yGfCWtf9ec3/oBrj/gd/wAi/f8A/X1/7Itdj4w58J61/wBeU3/oBrjPgaf+JJqIz/y8A4/4CK5p/wAePozoj/Bl6npVFFFdJzhRRRQAVw/imHyNaLgYEqh/x6H+VdxXOeNIA1pBOByj7T9CP/rVyY2HNSfkdGGly1PUq6XJlRWhOuVrE0qTpzW6fmSvMou6sddRWdzGnXa1IvKGp7tcGoE6VhNWZpF3Ri6xHlGqj4YnNrq0L9lcZ+mea1tTXKtXPQny7sduaUXZ3Rpa6se0UVX0+b7RYwS5zvQE/XFWK+lTuro8VqzsFFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUddm+zaHqM4OPKt5H/JSavVieNpRF4Q1lietrIv5qR/Wpm7RbKirtI4P4Ew8axP/ANckH/jxP9K9Xrzn4Hw7fDt9KRy90V/AIv8Aia9GrHCq1JGmId6jCiiiugxCiiigAooooAKKKKACiiigAooooAKKKKAMrxYM+FdZH/TlN/6Aa4f4GH/iV6ovpMp/8druvFA3eGtWHraTD/xw1wHwKb/Q9XX0kjP6N/hXLP8Ajx+Z0Q/gy+R6lRRRXUc4UUUUAFUNdt/tOk3KAZYLuH1HP9Kv0EZGD0qZx5ouL6ji+VpnnemyYYCungO6L8K5ieL7Jqc8I6I5A+nat+wkygFeBT9yVmepU95XQl0maqquK0Z1yKpsuDTrLqKDMvUEyprlbseXcZ966TxFpFlq9ssWoQ+dGjb1G5lwcY7EetcLqXg3QkP/ACD1K+jSOwP1BNZK3U1TfQ9j8GT+foUXrGxT+v8AWtyvKfAPgvwtdwXUdxoOnyMhVgWiB65/wrrP+Fd+EP8AoXNN/wC/Ir3sNLmpRaPLrq1RnVUVyn/CufBPV/CPh+Rj1aXT4nY/UspNL/wrjwP/ANCb4b/8FcH/AMTW5kdNNNFAm+eRI0zjLsAM/jVHxHqD6d4a1TUbXy3ktrSW4j3cqxVCwzg8jjsayofh94MgffD4R8Oxv03JpsIP/oNa2r6XHfeHb3SYSltFcWr2qFE4iDIVGF44GenHSgDy34cfFP8Atnw1Br3iXxX4ShRbSS6u9KtIGF1Aq57m4Y9gceXk5ArXi+MuheXcteabrVjJHpJ1uGK5hjDXVqM/NHtkIzx91iprT0b4d2lp8JU8CajeSXlp9ke1kuY08piGYtuC5bBBI7np+FctYfBcW3h650kXugRLJp02nreWnh6OC6cOm0PLL5hLkDrt2bj1NAGpbfGXR7iS3iTRdeE11pX9sWsZihzPbgEsVPm4DAK3DFc44zkZvaR8WPD+r6r4SsLGLUHfxLby3FnIYlCRiMMXWTLZBBRhwGGe+OaybL4Q/ZtR0G6/tzd/Zfh5tB2/ZMeblWHm538fe+7z061W0b4NSaN/wgtxp/iBRqPhdLiITS2O6O5jmLkjYJAUIDtg7j9O1AE0fx28OS6Tod/b6T4huBrM9xb2sEFoksxeHbuBRXJ53jGM984r07SL3+0tKs777NdWn2mFJvs91H5c0W4A7XX+FhnBHY15J4X+CH9hf8IX/wAVB5//AAjl9dXn/Hlt+0eds+X/AFh2Y2dec56CvZqACiiigAooooAKKKKACuV+KMvk+BtTPQsET83WuqrhfjLL5fg7Zn/W3MafzP8ASsqztTl6GlJXmiT4PxeX4Khf/nrNI/64/pXbVzPw1h8nwPpS46xs/wD30zH+tdNToq1OK8gqu82FFFFaGYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBR11d+h6ivrbSD/AMdNebfAlvl1pfeE/wDoden6ku/TrpP70TD9DXlXwJb/AEnWF9UiP6tXLU/jQ+Z0U/4Uvkeu0UUV1HOFFFFABRRRQBw/iqLydbLjpKiv/T+lWdNfIWp/G0P/AB6zgdCUP8x/WqOlNkCvBxMeSsz1KT5qSN1lytU5k5q/FylQTpjNa1I3jcyi7OxmXK5Q1zWrJ8prqZx8prntTXKtXCdUSx8PJ/L1aSIniSMgfUc/416LXknhq4+y69auTgeYFP0PH9a9br2cBK9NrszhxkbTuFeS6/CviT9onRtJ1Ib9O0LRm1iCBh8sly83lByO+0YI9DXrVch4j8GtqXjjQfFOm6gLDUdNR7ecGDzVu7Z+TE3zLjByQ3OCehruOQ8P1e/8R33hf43RanrKXdhZXEkKwSRSEp6CItKRGg7rtOfUVe0Hxrqdl4ZsPB+q2emX2k3XgIalBtWWNwBbspjlIf5gQh5XYRnjpmvY774ceFr271m4n06UPrKbNQSK8njjuRjGWjVwu7/axnk88ml/4Vz4V861l/sv95baWdFiP2iX5bMgr5X3ueGPzH5uetAHkngf4iasNL8OeHfDGn6Rp0dv4afWrhp4ppo1RWYCKJTKG6gfMzt16HFYdr4l1nxp8Rvg/rv/ABL7XWb6w1Fh+5drdGAmUfJv3EYUcbvxr1XxT8JbO/tdOtvD0ljo8djYvp8MrQXM06RNnKB1uY9y8n5ZA4yT6kVr+Fvhj4c8Pw+GWS3kub/w/A8FndySsGUSbvMJVSFOd7dQcZoAZ8FPGt34+8A2ut6lawW140skMqW5Plko2MqCSQD6En614j8E/GWreD/AfgxIorG60jWdfl02SHy3FyjO/EitvwQO67O3Xnj6Q8JeGNH8I6OuleHrT7HYK7SCLzXk+ZjknLkn9awdB+Ffg7QruwuNN0l1awkeW1Sa8nnjgdvvOkcjsgY8fMBngUAee23xk1x9JsvE8llpv/COXWv/ANiiyWN/taIc4l8zftJ4PybB/vVSm+M/ii3tNY1N7PRZLHTfE39iNAsMqySQknDh/MIDDH90g56DHPrEPw48KQ6wupx6SFuFujfKnny+Qtweswh3eWH/ANoLmopfhh4Plsb6zfSM217qH9qXCfaZvnueT5md+R1PyjA9qAPOtU+MPiWTXvECeHNAfUbTRdUGnPYw6Xd3E9wqkiWQTx/u48EfKrAkjn67mrRp4d/aK8OyaWPKj8UWFzFqEKcLI8C70lYf3sfLn0/Guw1H4eeGdQ1K9vprCaO4vipuxbXs9vHclenmxxuqSf8AAgc0yDwa7/Embxdqeo/a3itPsWn2iw+WlohOXYncd7se+FwOMHjAB19FFFABRRRQAV5r8cpduiadDn79wWx9FI/9mr0qvJvjrLmTRoR6SsR/3yB/WufFO1Jm2HV6iPQ/CUXkeFtIjxjbaRZ/75Fa1QWMXkWVvEP+Wcar+QxU9bxVkkZSd22FFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA2UbonHqCK8e+BrbdX1SM94FP5N/9evY68a+Df7vxhqkXpbv+kij+tctb+LB+p0Uv4c16HstFFFdRzhRRRQAUUUUAZHiqHzdGlIHMZDj88fyJrmNKf5gK7m6hFxbSwt0kUr+dee2BMc+xuCpwRXk5hG01Lud+EleLidhanK06Zcg1Ws34FXGwVopvmhYmStIy7heDXP6inJrprletYOop1rgmrM6oO5yj5iuQy8EHIr2Ozm+0WkEw/5aIr/mM14/qA2yV6d4Rn8/w9aMTkqpQ/gcfyxXfl0vecTDGL3UzYooor1jzwooooAKKKKACiiigAooooAKKKKACiiigAooooAK8f8Ai9/pPjLRrTsY0GP96Qj+lewV4542b7R8XdKj6iOW1THtvDf1rmxfwW7tHRhvjv5HsdFFFdJzhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV498Ml8n4lazGeoSdPylX/AAr2GvH/AAt/ovxk1CLp5stwPzy/9K5q/wAcH5nRR+Ga8j2Ciiiuk5wooooAKKKKACvP9UiNrr1yp6M+8fQ8/wBa9ArkfGkOy7tbgD7wKH8Dkfzrix8OalfsdOFladu5YsXyorTjOVrE018oK2IDXBh5dDoqoiuV61iaknymuguFyKx79MoaivG0iqT0OL1Vea7P4cXPmabcQE8xuGH0I/8ArVymqpwa1fh1N5eqSwk8SRnj3BB/xp4OXLVRWIjzU2ei0UUV7x5QUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeM3f8ApnxuQddlwn/jkYP9K9mrxvwyDdfGa9kP/LKe4P5BlrlxOrgvM6KGik/I9kooorqOcKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvH7j/AEP44I3QSSr+O6HH8zXsFeP+Pf8AQ/itpFx0Dm3cn/gZU/oK5sVpGL7NHRh92u6Z7BRRRXSc4UUUUAFFFFABWH4wh83Ry4HMTq/4dP61uVU1eLztLu09Ymx9ccVnWjzQaLpvlmmcjpEmVAzXQQGuT0l8MBXUWrZArwqLtI9Gqi3IMpWXdpkGtYcrVG7XrXRiI3VzKk7OxyGqRfeqp4Wn+zeILRvWTYf+Bcf1rY1SPINcxva3vEkXhlYMPqDXHCXLJS7HXbmi0ez0UyCRZoI5U5V1DD6Gn19LueKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXj/AMMP9K+Ius3XUbZn/FpR/wDXr124kEUEkh6IpY/gK8l+BkZkvtYuD1CRr/30WP8ASuatrUgvU6KWlObPXaKKK6TnCiiigAooooAKKKKACiiigAooooAKKKKACiiigAryD42KbfXNHu16+WQD/uMD/wCzV6/XmHx0g3afpU+PuSun/fQB/wDZa58Ur0mb4Z2qI9ORg6Kw6MARS1neG5vtPh7TJs58y2jY/iorRrdO6uYtWdgooopiCiiigApGUOpVhkEYNLRQB5tAhtr2WE9Y3K/ka6aybKisbxHF9n1+UjhZAHH9f1BrQ06TKCvnnH2dRx7Hqt88EzbjPFQXa8VJEeBS3Ayldsvegcy0kc5qSZU1x+optlJruL5Mg1yerR9TXmvc7oM9B8IXH2nw9aMTygKH8DgfpitmuQ+G8+/T7qAnmOQNj6j/AOtXX19Bh5c1KLPKrR5ajQUUUVsZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGZ4om+z+GtVl7paykfXYa4X4GQ7dJ1Ob+/Oqf98rn/2auo+JE3keCNWbON0YT/vpgP61k/BmHyvB5fH+tuXf8gF/pXNLWvFdkbx0ov1O7ooorpMAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4D41xF/CcDgf6u7Rj9Nrj+td/XI/FWDzvA2oHvGY3H4OP6E1lXV6cvQ0ou00WvhxP9o8E6S/8AdiMf/fLFf6V0lcP8HJ/N8GIn/PGeRP5N/wCzV3FOi704vyCqrTaCiiitDMKKKKACiiigDk/HEWJbScDjlCf1H9aqaXJ8orb8Yw+boxcdYnV/6f1rmdKk6CvExseWs33PSw75qdux1VueBU78pVO2bgVcByK1pO8bGU1ZmVeL1rl9VjyrV1t2vWud1JMhq4Zq0jqpvQb8OpDHrFxET8rwk49wR/8AXr0WvLvC0v2fxLanOA7FPzBFeo16+AlelbszixatO4UUUV2nKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcP8Y5/K8GOn/PaeNPyy3/staHwyg8jwPpa45ZWf/vp2P9a5n453G3S9Lts/6yZpMf7q4/8AZq7jwlF5HhbSIyMFbSLI99gzXNHWu/JHRLSivNmtRRRXSc4UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYvjSD7R4S1ePGSbWQge4UkfyraqG8hFxZzwHpJGyfmMVMldNDi7NM89+B0wbw/fw90ut/5oo/8AZa9IryT4GTFLnWLZupWN8fQsD/MV63WOFd6SNcQrVGFFFFdBiFFFFABRRRQBU1aLz9Muo8ZLRtj644rz7Tnw4r0wjIIPQ15kYza30sLdY3K/ka8vMY6xkd2DejR1Vo2VFX0PFZFg2UFakZrnoSLqrUiuRkGsHUU4NdHMMisXUE4NZ11Z3KpM46V2tr2OZOGRww+oNevW8qzwRyocrIoYfQivJdVTDZr0PwbcfafD1qT96MGM/geP0xXVl8/ecSMZG8VI26KKK9Y88KKKKACiiigAooooAKKKKACiiigAoqG8kMVpNIrxoyoSrSnCA44z7Vm6Be3V5Ldm5aIrHsVPKIKtwTuGCeoK8ZPTPGalys7DSurnmnxpd7rxLpVgnJ8kFR7u5H/sor2CGNYYY40GFRQo+gryHXP+Jt8Z7SAfMtvLEPwRfMP65r2GuehrOcvP8jetpGEfIKKKK6jnCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8f+G3+g/ErWLPopE8YH+7ICP0Br2CvHrb/QPje69Fllb8d8Wf5mvYa5sLpFx7NnRiNWn3QUUUV0nOFFFFABRRRQAVwfieHyddkYdJAr/pj+ld5XLeNLf5re5A9Y2/mP61x46PNSv2OjCytU9SvpzfIK1ojWDpj8CtqI8V5NJ2Z21EWW5Wsy/T5TWkp4qpeLlTW1ZXVzKm7M4zVY8g103w4m3afdQHrHKH/Mf/AGNYmpx5zVjwFP5OsyQE4E0ZwPcc/wAs1OEly1Ua11zU2ehUUUV7x5QUUUUAFFFFABRRRQAUUUUAFFFFAFDXFkfTJBDKsUm5CpZguSGBwCeAT0B9TTtIdXtCRvD7yHEiKrq3cNt4J9xwaq+JkmlsEjigWZWkG8FSxUAEggDn7wAzg4zyCMis2G4GmeA7u8XzFIgmmUyH5+c7A3uBtHtjFZOVpfI0SvH5nDfDj/ibfEjVNSPKJ5sqn03NgfoTXsVeX/Ay026fql4RzJKsIP8AujJ/9CFeoVnhV+7u+peIfv27BRRRXSYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAePeOSLD4s6Vc9BI1vIT7b9p/Ra9hrxz42I0HiDSrxeCYNoPuj5/wDZq9ghkEsKSL0dQw/GuWhpUmvM6KusIMfRRRXUc4UUUUAFFFFABWZ4kh8/R7gAcoA4/D/62a06ZPGJoJIz0dSv5ioqR54uPcqEuWSZwOmthgK34TwK5y0DRzlGGGU4Nb8B4FfOxdmerPUuoajuRlTTkNEoytdL1iYLRnOajHnNZ2kN9l120kJwBIAfoeP61u3seQeKwbqFg4Kg5rmi3GSa6HRurHqFFRWkhltYZD1dFY/iKlr6RO6ueO9AooopgFFFFABRRRQAUUUUAFRXUnlW8jiSOIhTh5Puqe2eRxn3qWq9/Zw39s0FypaMkHhiCCDkHI9xSe2gLfU5a4kkvb+yub3zopIgyGKKT5R8wR5I3AByp4Ib+Ekgetf4rzJp3gVraBdiTSR26gdgPm/ktWbIw/2tBpGmh5bS1mLq7ciDYMOm4/ezvAA6jLdgK5r45Xh8vSrBOSzPMw+mFX+bVyVJWpSZ1QV6kUdH8JbP7J4KtnIw1w7zH89o/RRXZVS0SzGn6NY2Y/5YQpH+IABq7XTTjywUTnnLmk2FFFFWSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5f8AHSDdp+lXGPuSvHn/AHgD/wCy13nhWUz+GdJlJyzWkRP12DNcz8ZLfzvBxkAz5Fwkn81/9mrU+Gs/n+CNLY9VQp/3yxH9K5o6V5eaOiWtFeTOmooorpOcKKKKACiiigAooooA5XUNOK6jK6jhm3fnzVqG3IUcVtywrIckc0ggArgng05No6ViHaxnJEak8kkdKvCEU7yxVRwtiXWMaaz3dqgOlhjytdD5Ypdg9KccJFA67I7VPLt40/uqBUtFFdaVlYweoUUUUwCiiigAooooAKKKKACsGG3lmvdQMV1Jb38c2VydyNGVG3KHgrwRkYOQ2D1reqre6fbXjI08Z8xBhZEYo6juAykEfnUyVyouxBos1zc25uLwLHISYzDG+9EKkhiDtB5OfXoMV5d4r/4nnxdsrIfPHA8UbDthf3jfzIr16GKO3gSKJQkca4A9AK8k+HMban8SNW1FwSsfmyK3oWbAH/fJNc9dX5Id2bUXbmn2R6/RRRXUc4UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBkeLbH+0vDl/a4yXjOPqORWZ8NLZrPwtFbyAhkkbg+5zXUsAwIPQ1BZ2y2yMqYAJzWbh7/OWpe7yliiiitCAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCC+YrZTlc52HGPXFYPgjR49MtLiVUxJcPk59B0/rXSkZGDQAAMAYFS4pyUilKysFFFFUSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows the location of the pelvis, hip joint, and femur (thigh bone).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_48_3841=[""].join("\n");
var outline_f3_48_3841=null;
var title_f3_48_3842="Through and through retention sutures";
var content_f3_48_3842=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Through and through retention sutures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_48_3842=[""].join("\n");
var outline_f3_48_3842=null;
var title_f3_48_3843="TPO Gross";
var content_f3_48_3843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tracheopathia osteochondroplastic",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 251px; height: 426px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pathologic specimen with characteristic lateral tracheal wall thickening.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Luis LG Fajardo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_48_3843=[""].join("\n");
var outline_f3_48_3843=null;
var title_f3_48_3844="Epidermal nevus on neck";
var content_f3_48_3844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Epidermal nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hyperpigmented, verrucous, linear plaque is present on the neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_48_3844=[""].join("\n");
var outline_f3_48_3844=null;
var title_f3_48_3845="Biventricular pacemaker PI";
var content_f3_48_3845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F68651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F68651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Biventricular pacemaker",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 641px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A biventricular (or \"BiV\") pacemaker is a device that is used to treat some types of heart failure. The device uses electrical signals to help the heart pump better. The electrical signals travel from a battery to the heart through 3 wires (called \"leads\") that are put in different parts of the heart. The right atrial lead carries electrical signals to the right upper chamber (right atrium). The coronary sinus and right ventricular leads carry electrical signals to the heart's lower chambers (ventricles).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_48_3845=[""].join("\n");
var outline_f3_48_3845=null;
var title_f3_48_3846="Dystrophin associated protein";
var content_f3_48_3846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    The dystrophin associated protein complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dystrophin is located on the cytoplasmic face of the plasma membrane of muscle fibers. Arrows indicate the protein components mutated in various muscular dystrophies. Alterations in the dystrophin gene cause Becker and Duchenne muscular dystrophies. Mutations in the sarcoglycan proteins, caveolin-3 and dysferlin, lead to limb girdle muscular dystrophies. The laminin a2-chain is mutated in a subtype of congenital muscular dystrophy without structural brain anomalies, as is a7-integrin.",
"    <div class=\"footnotes\">",
"     BMD: Becker muscular dystrophy; CMD: congenital muscular dystrophy; COOH: carboxy-terminal domain; CR: cysteine-rich domain; DMD: Duchenne muscular dystrophy; HH: two helices of the coiled-coil domain; LGMD: limb-girdle muscular dystrophy; MM: Miyoshi myopathy; NH2: amino-terminal domain; Syn: syntrophin-binding domain.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. K. O'Brien and Dr. L. Kunkel, Children's Hospital, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_48_3846=[""].join("\n");
var outline_f3_48_3846=null;
var title_f3_48_3847="Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment";
var content_f3_48_3847=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/48/3847/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/48/3847/contributors\">",
"     Petra Feyer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/48/3847/contributors\">",
"     Karin Jordan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/48/3847/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/48/3847/contributors\">",
"     Paul J Hesketh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/48/3847/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/48/3847/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/48/3847/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/48/3847/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea and vomiting caused by radiation therapy (RT) are generally less severe than that caused by chemotherapy. However, these side effects are clinically important and can be distressing for patients. Furthermore, RT-induced nausea and vomiting (RINV) can cause patients to delay or refuse further treatment.",
"   </p>",
"   <p>",
"    The incidence, classification of risk, and management of RINV are discussed here. The approach to chemotherapy-induced nausea and vomiting are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of RINV is incompletely understood but is thought to be similar to that caused by chemotherapy. Progress in understanding the pathophysiology of chemotherapy-induced emesis led to the development of agents that form the basis for treatment of RINV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39894?source=see_link\">",
"     \"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two prospective observational studies provide information on the frequency of RINV and the extent to which this problem is treated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Italian Group for Antiemetic Research in Radiotherapy (IGARR) analyzed the incidence of RINV in 1020 patients receiving various kinds of RT [",
"      <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/1\">",
"       1",
"      </a>",
"      ]. Overall, nausea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting was reported by 28 percent. The median time to the first episode of vomiting was three days. Antiemetic drugs were administered to 17 percent of the patients, including 12 percent treated prophylactically and 5 percent given rescue therapy.",
"     </li>",
"     <li>",
"      In another series of 368 patients receiving RT, the overall incidence rates for nausea and vomiting were 39 and 7 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/2\">",
"       2",
"      </a>",
"      ]. Nausea was more frequent in those receiving RT to the lower abdomen or pelvis and to the head and neck area (66 and 48 percent, respectively). Importantly, only one-fourth of the patients reporting nausea felt that antiemetics had been beneficial and one-third would have liked additional treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence and severity of RINV depend upon details of the treatment (irradiated site and volume, single and total dose, fractionation schedule, techniques). Patient-related factors (gender, general health of the patient, age, concurrent or recent chemotherapy, psychological state, tumor stage, history of prior treatment-related nausea) are also important.",
"   </p>",
"   <p>",
"    The most important factor appears to be the radiation field. The 2009 guidelines from the Multinational Association for Supportive Care in Cancer (MASCC) and the European Society for Medical Oncology (ESMO), which have been subsequently endorsed by the American Society of Clinical Oncology (ASCO) in 2011, divide the risk of emesis due to RT into four categories [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High (risk &gt;90 percent) &mdash; Total body irradiation (TBI)",
"     </li>",
"     <li>",
"      Moderate (risk 60 to 90 percent) &mdash; Upper abdominal irradiation, hemi-body irradiation (HBI) and upper body irradiation (UBI)",
"     </li>",
"     <li>",
"      Low (risk 30 to 60 percent) &mdash; Cranium (all), craniospinal, head and neck, lower thorax region, pelvis",
"     </li>",
"     <li>",
"      Minimal (risk &lt;30 percent) &mdash; Other sites, including breast and extremities",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREVENTION AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only limited data from randomized trials that have evaluated the efficacy of various antiemetic drugs in preventing RINV (",
"    <a class=\"graphic graphic_table graphicRef82679 \" href=\"UTD.htm?35/5/35933\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73445 \" href=\"UTD.htm?4/6/4205\">",
"     table 2",
"    </a>",
"    ). Generally, these trials were conducted in patients at moderate or high risk for RINV.",
"   </p>",
"   <p>",
"    The available evidence from these trials indicates that 5-hydroxytryptamine (5-HT3) receptor antagonists are the most active agents that have been evaluated in randomized trials. However, other agents also may have a role in some settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     5HT3 receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results with 5-HT3 receptor antagonists were analyzed in a meta-analysis that included nine trials [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/5\">",
"     5",
"    </a>",
"    ]. In this meta-analysis, fewer patients had residual emesis compared with placebo (40 versus 57 percent, relative risk [RR] 0.7, 95% CI 0.57-0.86) and fewer required rescue medication (6.5 versus 36 percent, RR 0.18, 95% CI 0.05-0.60). Despite treatment, most patients did develop RT-induced nausea (70 versus 83 percent with placebo, RR 0.84, 95% CI 0.73-0.96).",
"   </p>",
"   <p>",
"    The underlying incidence of nausea and vomiting in these trials is heavily influenced by the study populations (",
"    <a class=\"graphic graphic_table graphicRef82679 \" href=\"UTD.htm?35/5/35933\">",
"     table 1",
"    </a>",
"    ). Taken together, these trials show 5-HT3 receptor antagonists have significantly greater protective effect against RINV for patients receiving upper abdomen irradiation than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , phenothiazines or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. Similarly, 5-HT3 receptor antagonists provided significantly better protection against RINV caused by TBI or HBI than conventional antiemetics or placebo (",
"    <a class=\"graphic graphic_table graphicRef73445 \" href=\"UTD.htm?4/6/4205\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. Separate analyses of trials comparing 5HT3 receptor antagonists with metoclopramide also demonstrated a statistically significant benefit for the control of vomiting.",
"   </p>",
"   <p>",
"    The adverse effects of 5-HT3 receptor antagonists are generally mild, consisting mainly of headache, constipation, diarrhea, and asthenia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/11,12,14,17,18\">",
"     11,12,14,17,18",
"    </a>",
"    ]. In some patients, 5-HT3 receptor antagonists reduced the frequency of diarrhea, a troublesome side effect due to acute radiation enterotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/8,19\">",
"     8,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials in RINV have utilized four different 5HT3 receptor antagonists (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    , tropisetron). These agents have not been compared with each other and there are inadequate data to define an optimal doses and schedules [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/5\">",
"     5",
"    </a>",
"    ]. There currently are no available data on the appropriate dosing frequency with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/18/34085?source=see_link\">",
"     palonosetron",
"    </a>",
"    in this setting. The updated ASCO guideline suggests that dosing every second or third day may be appropriate for this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=see_link\">",
"     Dolasetron",
"    </a>",
"    can affect the electrical activity of the heart by prolonging the QT, QRS, and PR intervals, which may result in abnormal heart rhythms. Due to the risk of QT prolongation from increased drug exposure (which may result in torsade de points), the injectable form of dolasetron is contraindicated for prophylaxis of RINV [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/20\">",
"     20",
"    </a>",
"    ]. The risk of developing an abnormal heart rhythm with oral dolasetron is less than that seen with the injection form. However, there is still a potential risk.",
"   </p>",
"   <p>",
"    The US Food and Drug Administration recommends the following precautions in patients receiving oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potassium and magnesium levels should be assessed, and if abnormal, corrected before initiation of treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=see_link\">",
"       dolasetron",
"      </a>",
"      . These electrolytes should be monitored after administration as clinically indicated.",
"     </li>",
"     <li>",
"      Use electrocardiographic monitoring in patients with heart failure, a slow heart rate, underlying cardiac disease, the elderly, and in patients with renal impairment.",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=see_link\">",
"       dolasetron",
"      </a>",
"      should be avoided in patients with congenital long-QT syndrome (",
"      <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Drugs known to prolong the PR (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ) or QRS interval (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      ) should be avoided in patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=see_link\">",
"       dolasetron",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroids are an attractive option because of their widespread availability, low cost, and activity as antiemetics. One randomized trial showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    was significantly more effective than placebo in patients receiving RT to the upper abdomen (",
"    <a class=\"graphic graphic_table graphicRef82679 \" href=\"UTD.htm?35/5/35933\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combining corticosteroids with a 5-HT3 receptor antagonists was assessed in a trial in which a five-day course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    was compared to ondansetron plus placebo in 211 patients who received RT to the upper abdomen (",
"    <a class=\"graphic graphic_table graphicRef73445 \" href=\"UTD.htm?4/6/4205\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/22\">",
"     22",
"    </a>",
"    ]. During the first five days, there was a statistically nonsignificant trend toward complete control of nausea (50 versus 38 percent with placebo) and vomiting (78 versus 71 percent), which was the primary objective of the trial. The effects of dexamethasone extended beyond the initial five day period, and significantly more patients had complete control of emesis over the entire course of radiotherapy (23 versus 12 percent, with placebo), a secondary objective of the trial. Although this study did not demonstrate a statistically significant benefit for the primary end point, the results strongly suggest that the addition of dexamethasone was beneficial.",
"   </p>",
"   <p>",
"    Since emesis is more frequent early in treatment, prophylactic antiemetics may not be necessary for a full course of RT, and treatment for the first week may be sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/21,23,24\">",
"     21,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neurokinin-1 receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurokinin-1 (NK-1) receptor antagonists have an established role in the management of chemotherapy-induced nausea and vomiting (CINV). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\", section on 'Neurokinin-1 receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    None of the NK-1 receptor antagonists have been adequately evaluated in patients at risk for RINV. Although preclinical data indicate that RINV is mediated in part by substance P [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/25\">",
"     25",
"    </a>",
"    ], these agents cannot be recommended at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older, less specific antiemetic drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , and cannabinoids have shown limited efficacy in the prevention or treatment of RINV, although they may have a role in patients with milder symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Duration of prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate duration of antiemetic prophylaxis for patients receiving fractionated radiotherapy is not clear. There have been no randomized trials using 5-HT3 receptor antagonists that compared a five-day course of treatment with a more protracted course. The decision on whether or not to continue antiemetic prophylaxis beyond the first week should be based upon an assessment of the risk of emesis as well as relevant individual factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Rescue therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of 5-HT3 receptor antagonists once nausea or vomiting occurs has been suggested in all studies, but there are no trials specifically in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The role of rescue medication for patients at low and minimal risk of RINV needs to be defined in further studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GUIDELINES AND PATIENT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of newer antiemetic agents and a better understanding of their activity as a function of the emetogenicity of different RT regimens has led to the generation of guidelines for patient management [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/3,4,23\">",
"     3,4,23",
"    </a>",
"    ]. The most recent such guidelines were promulgated by the Multinational Association for Supportive Care in Cancer (MASCC) and European Society for Medical Oncology (ESMO) in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/3\">",
"     3",
"    </a>",
"    ] and which were subsequently endorsed by the American Society of Clinical Oncology (ASCO) in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/4,30\">",
"     4,30",
"    </a>",
"    ]. These guidelines are presented in the following table and incorporated into our recommendations (",
"    <a class=\"graphic graphic_table graphicRef51412 \" href=\"UTD.htm?23/57/24475\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The risk of nausea and vomiting for a patient being treated with RT depends upon multiple other factors in addition to the emetogenicity of the specific RT regimen. Patient-specific factors include the simultaneous administration of chemotherapy, age, gender, alcohol consumption, anxiety, and previous experience of nausea and vomiting (",
"    <a class=\"graphic graphic_table graphicRef81948 \" href=\"UTD.htm?31/60/32715\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3847/abstract/24,31,32\">",
"     24,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The four risk categories based upon the RT regimen can be modified to incorporate these patient-specific factors. Although not prospectively proven, an approach taking these risk factors into account might further improve emesis prophylaxis in patients receiving RT (",
"    <a class=\"graphic graphic_figure graphicRef70623 \" href=\"UTD.htm?12/38/12911\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=see_link\">",
"       \"Patient information: Nausea and vomiting with cancer treatment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation-induced nausea and vomiting (RINV) is a frequent complication of radiation therapy (RT). Its incidence and severity is influenced by the specific RT regimen and by patient-specific factors (",
"    <a class=\"graphic graphic_table graphicRef51412 \" href=\"UTD.htm?23/57/24475\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81948 \" href=\"UTD.htm?31/60/32715\">",
"     table 5",
"    </a>",
"    ). Patients should receive antiemetic prophylaxis based upon an individualized assessment of risk, taking into account both the planned RT regimen and patient-specific factors. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk classification'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'Guidelines and patient management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients at high risk of developing RINV (",
"      <a class=\"graphic graphic_table graphicRef51412 \" href=\"UTD.htm?23/57/24475\">",
"       table 4",
"      </a>",
"      ), we recommend prophylaxis with a 5-hydroxytryptamine (5-HT3) receptor antagonist (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Based upon results from patients receiving highly emetogenic chemotherapy, we suggest the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      to the 5-HT3 receptor antagonist (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). There are no comparative clinical trials data on the use of neurokinin-1 (NK1) receptor antagonists in preventing RINV. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk classification'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"       \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients at moderate risk of developing RINV (",
"      <a class=\"graphic graphic_table graphicRef51412 \" href=\"UTD.htm?23/57/24475\">",
"       table 4",
"      </a>",
"      ), we recommend prophylaxis with a 5-HT3 receptor antagonist (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In this risk group, the addition of short course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      to the 5-HT3 receptor antagonist may be offered during fractions one to five. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients at low risk of developing RINV (",
"      <a class=\"graphic graphic_table graphicRef51412 \" href=\"UTD.htm?23/57/24475\">",
"       table 4",
"      </a>",
"      ), we suggest prophylaxis with a 5-HT3 receptor antagonist (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Based upon an individualized assessment of risk, observation with rescue treatment using a 5-HT3 receptor antagonist if necessary is an appropriate alternative. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Guidelines and patient management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients at minimal risk of developing RINV (",
"      <a class=\"graphic graphic_table graphicRef51412 \" href=\"UTD.htm?23/57/24475\">",
"       table 4",
"      </a>",
"      ), we suggest NOT treating prophylactically (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If patients develop RINV, we suggest treatment with a dopamine receptor antagonist or a 5-HT3 receptor antagonist (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Guidelines and patient management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients being treated with concomitant RT and chemotherapy, antiemetic prophylaxis should be based upon the higher chemotherapy or RT risk category. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Guidelines and patient management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"       \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/1\">",
"      Maranzano E, De Angelis V, Pergolizzi S, et al. A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiother Oncol 2010; 94:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/2\">",
"      Enblom A, Bergius Axelsson B, Steineck G, et al. One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient. Support Care Cancer 2009; 17:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/3\">",
"      Feyer PC, Maranzano E, Molassiotis A, et al. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer 2011; 19 Suppl 1:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/4\">",
"      Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29:4189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/5\">",
"      Salvo N, Doble B, Khan L, et al. Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials. Int J Radiat Oncol Biol Phys 2012; 82:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/6\">",
"      Aass N, H&aring;tun DE, Thoresen M, Foss&aring; SD. Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients. Radiother Oncol 1997; 45:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/7\">",
"      Bey P, Wilkinson PM, Resbeut M, et al. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer 1996; 4:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/8\">",
"      Franz&eacute;n L, Nyman J, Hagberg H, et al. A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol 1996; 7:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/9\">",
"      Lanciano R, Sherman DM, Michalski J, et al. The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy. Cancer Invest 2001; 19:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/10\">",
"      Priestman TJ, Roberts JT, Lucraft H, et al. Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol (R Coll Radiol) 1990; 2:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/11\">",
"      Priestman TJ, Roberts JT, Upadhyaya BK. A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin Oncol (R Coll Radiol) 1993; 5:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/12\">",
"      Prentice HG, Cunningham S, Gandhi L, et al. Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant 1995; 15:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/13\">",
"      Spitzer TR, Bryson JC, Cirenza E, et al. Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. J Clin Oncol 1994; 12:2432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/14\">",
"      Spitzer TR, Friedman CJ, Bushnell W, et al. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant 2000; 26:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/15\">",
"      Sykes AJ, Kiltie AE, Stewart AL. Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. Support Care Cancer 1997; 5:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/16\">",
"      Tiley C, Powles R, Catalano J, et al. Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation. Leuk Lymphoma 1992; 7:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/17\">",
"      Goodin S, Cunningham R. 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist 2002; 7:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/18\">",
"      Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 2007; 61:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/19\">",
"      Feyer PC, Stewart AL, Titlbach OJ. Aetiology and prevention of emesis induced by radiotherapy. Support Care Cancer 1998; 6:253.",
"     </a>",
"    </li>",
"    <li>",
"     FDA safety communication available online at file://www.fda.gov/Drugs/DrugSafety/ucm237081.htm (Accessed on December 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/21\">",
"      Kirkbride P, Bezjak A, Pater J, et al. Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group phase III study. J Clin Oncol 2000; 18:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/22\">",
"      National Cancer Institute of Canada Clinical Trials Group (SC19), Wong RK, Paul N, et al. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol 2006; 24:3458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/23\">",
"      American Society of Clinical Oncology, Kris MG, Hesketh PJ, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24:2932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/24\">",
"      Feyer PCh, Maranzano E, Molassiotis A, et al. Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. Support Care Cancer 2005; 13:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/25\">",
"      Yamamoto K, Nohara K, Furuya T, Yamatodani A. Ondansetron, dexamethasone and an NK1 antagonist block radiation sickness in mice. Pharmacol Biochem Behav 2005; 82:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/26\">",
"      Roila F, Ciccarese G, Palladino MA, De Angelis V. Prevention of radiotherapy-induced emesis. Tumori 1998; 84:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/27\">",
"      LeBourgeois JP, McKenna CJ, Coster B, et al. Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment. Clin Oncol (R Coll Radiol) 1999; 11:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/28\">",
"      Maranzano E, Feyer PCh, Molassiotis A, et al. Evidence-based recommendations for the use of antiemetics in radiotherapy. Radiother Oncol 2005; 76:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/29\">",
"      Mystakidou K, Katsouda E, Linou A, et al. Prophylactic tropisetron versus rescue tropisetron in fractionated radiotherapy to moderate or high emetogenic areas: a prospective randomized open label study in cancer patients. Med Oncol 2006; 23:251.",
"     </a>",
"    </li>",
"    <li>",
"     ASCO guidelines file://www.asco.org/ASCOv2/Department%20Content/Cancer%20Policy%20and%20Clinical%20Affairs/Downloads/Guideline%20Tools%20and%20Resources/Antiemetics/2011/Antiemetics%20Full%20Guideline%20Update%2092211.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/31\">",
"      Jordan K, Kinitz I, Voigt W, et al. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 2009; 45:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3847/abstract/32\">",
"      Maranzano E. Radiation-induced emesis: a problem with many open questions. Tumori 2001; 87:213.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7052 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_48_3847=[""].join("\n");
var outline_f3_48_3847=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREVENTION AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      5HT3 receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neurokinin-1 receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Duration of prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Rescue therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GUIDELINES AND PATIENT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7052\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7052|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/38/12911\" title=\"figure 1\">",
"      Risk strat RINV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7052|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/5/35933\" title=\"table 1\">",
"      UAI RAD NV trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/6/4205\" title=\"table 2\">",
"      TBI HBI RAD NV trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 3\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/57/24475\" title=\"table 4\">",
"      RINV guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/60/32715\" title=\"table 5\">",
"      Emesis pt risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39894?source=related_link\">",
"      Pathophysiology and prediction of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_48_3848="Lichenoid drug eruption (drug-induced lichen planus)";
var content_f3_48_3848=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lichenoid drug eruption (drug-induced lichen planus)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/48/3848/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/48/3848/contributors\">",
"     Mirjana Ziemer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/48/3848/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/48/3848/contributors\">",
"     Maja Mockenhaupt, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/48/3848/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/48/3848/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/48/3848/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H29641535\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lichenoid drug eruption, also called drug-induced lichen planus, is an uncommon cutaneous adverse effect of several drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. It is characterized by a symmetric eruption of flat-topped, erythematous or violaceous papules resembling lichen planus on the trunk and extremities. The time interval between the initiation of the offending drug and the appearance of the cutaneous lesions varies from months to a year or more and depends upon the class of drug, dose, host reaction, and concurrent medications [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/3\">",
"     3",
"    </a>",
"    ]. Histologic examination reveals lichenoid interface dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the pathogenesis, clinical manifestations, diagnosis, and treatment of lichenoid drug eruptions. Lichen planus and other types of cutaneous adverse reactions to drugs are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=see_link\">",
"       \"Lichen planus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24360?source=see_link&amp;anchor=H198168284#H198168284\">",
"       \"Exanthematous (morbilliform) drug eruption\", section on 'Patient education'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/50/9000?source=see_link\">",
"       \"Fixed drug eruption\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43929?source=see_link\">",
"       \"Drug reaction with eosinophilia and systemic symptoms (DRESS)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42951?source=see_link\">",
"       \"Acute generalized exanthematous pustulosis (AGEP)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H286117\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of lichenoid drug eruption is not known. It occurs more frequently in older adults without sex predilection. In small case series, the average age at onset was 44 to 66 years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29641549\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29641558\">",
"    <span class=\"h2\">",
"     Immunologic mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenetic mechanism of lichenoid drug reaction is incompletely understood. T cells, keratinocytes, dendritic cells, and endothelial cells, which express activation markers, costimulatory molecules, and adhesion molecules (eg, MHC-class-II molecules, lymphocyte function-associated antigen [LFA] 1, L-selectin, intercellular adhesion molecule [ICAM] 1) are thought to be involved in the inflammatory reaction that ultimately leads to the apoptosis of basal keratinocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both CD4 and CD8 T cells are found at the dermoepidermal junction and within the epidermis. As in lichen planus, a persistent activation of CD8 autocytotoxic T lymphocytes against epidermal cells may be the crucial pathophysiologic factor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/10\">",
"     10",
"    </a>",
"    ]. Activated CD8 T cells induce the apoptosis of basal epidermal keratinocytes mainly through the",
"    <span class=\"nowrap\">",
"     perforin/granzyme",
"    </span>",
"    B pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. These cells also produce type I and type II cytokines, such as IFN-gamma and IL-5 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. IFN-gamma induces the expression of MHC-class-II molecules on keratinocytes and facilitates drug binding and presentation to CD4 T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasmacytoid dendritic cells are also thought to be involved in the early phase of lichenoid tissue reaction. They produce large amounts of type I interferons (IFN), such as IFN-alpha, which mediate the activation of IFN-gamma secreting cytotoxic T cells directly or through the maturation of myeloid dendritic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/14\">",
"     14",
"    </a>",
"    ]. TNF-alpha and other inflammatory cytokines and chemokines are responsible for the amplification of the inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/15-18\">",
"     15-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29641565\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lichenoid eruptions have been associated with a broad variety of drugs (",
"    <a class=\"graphic graphic_table graphicRef83762 \" href=\"UTD.htm?1/20/1357\">",
"     table 1",
"    </a>",
"    ), including [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/2-4,6,19-27\">",
"     2-4,6,19-27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ACE inhibitors",
"     </li>",
"     <li>",
"      Thiazide diuretics",
"     </li>",
"     <li>",
"      Antimalarials",
"     </li>",
"     <li>",
"      Beta blockers",
"     </li>",
"     <li>",
"      Gold salts",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       Penicillamine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cases induced by tumor necrosis factor-alpha antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , and lenercept) and tyrosine kinase inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ) have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/4,23,28,29\">",
"     4,23,28,29",
"    </a>",
"    ]. Lichenoid eruptions involving the oral mucosa have been associated with [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/6,24\">",
"     6,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       Allopurinol",
"      </a>",
"     </li>",
"     <li>",
"      ACE inhibitors",
"     </li>",
"     <li>",
"      Gold salts",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"     </li>",
"     <li>",
"      NSAIDs",
"     </li>",
"     <li>",
"      Anticonvulsants",
"     </li>",
"     <li>",
"      Antiretrovirals",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29641572\">",
"    <span class=\"h2\">",
"     Latency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The latency period between drug initiation and appearance of the eruption varies from months to a year or more and depends upon the type of drug, dosage, host reaction, previous exposure to the drug, and concurrent medications [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/3\">",
"     3",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    A latency period of two months to three years has been reported for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , three to six months for ACE inhibitors, and four to six weeks for quinacrine [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29641579\">",
"    <span class=\"h2\">",
"     Contribution of UV irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photosensitive lichenoid eruptions have been reported in patients taking a variety of drugs, in particular [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/6,30-33\">",
"     6,30-33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thiazide diuretics",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       Diltiazem",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       Quinine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       Quinidine",
"      </a>",
"     </li>",
"     <li>",
"      Tetracyclines",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       Ethambutol",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"       Chlorpromazine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The action spectrum for these drugs appears to be in the UVB wavelength range (290 to 320 nm) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29641593\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29641602\">",
"    <span class=\"h2\">",
"     Skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lichenoid drug eruption is characterized by a symmetric eruption of flat-topped, erythematous or violaceous papules, often grouped and confluent, on the trunk and extremities (",
"    <a class=\"graphic graphic_picture graphicRef83767 graphicRef83768 \" href=\"UTD.htm?8/48/8968\">",
"     picture 1A-B",
"    </a>",
"    ). Lesions closely resemble those seen in lichen planus (",
"    <a class=\"graphic graphic_picture graphicRef76383 graphicRef50632 \" href=\"UTD.htm?35/43/36536\">",
"     picture 2A-B",
"    </a>",
"    ), although in lichenoid drug eruption the individual lesions are less monomorphic and may have eczematous or psoriasiform morphology with marked desquamation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/35\">",
"     35",
"    </a>",
"    ]. Wickham striae (",
"    <a class=\"graphic graphic_picture graphicRef61523 \" href=\"UTD.htm?27/20/27968\">",
"     picture 3",
"    </a>",
"    ), consisting of fine, white lacelike patterns highly characteristic of lichen planus, are usually absent, but their presence does not exclude a drug-related etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The eruption can be localized or generalized, with a fairly symmetrical distribution. In some patients, the lesions are localized to the photoexposed areas and exhibit photoaggravation. In contrast to lichen planus, the lesions of lichenoid drug eruption are distributed on the extensor aspects of the extremities and dorsal aspects of the hands (",
"    <a class=\"graphic graphic_picture graphicRef76383 graphicRef83769 graphicRef59258 \" href=\"UTD.htm?31/58/32682\">",
"     picture 2A, 2C-D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/21\">",
"     21",
"    </a>",
"    ]. Nails are usually spared.",
"   </p>",
"   <p>",
"    Pruritus is frequent, although some patients are completely asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29641609\">",
"    <span class=\"h2\">",
"     Oral lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral lichenoid drug eruptions are rare. The lesions are identical to those of oral lichen planus and may have an erosive or reticular morphology (",
"    <a class=\"graphic graphic_picture graphicRef83774 \" href=\"UTD.htm?9/8/9349\">",
"     picture 4",
"    </a>",
"    ). Erosive lesions are associated with pain, burning, and irritation. Reticular forms are usually asymptomatic. Oral lichenoid drug eruptions have been associated with several drugs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    , ACE inhibitors, NSAIDs, anticonvulsants, and antiretrovirals [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/6,24\">",
"     6,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71523368\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eruption resolves in weeks to months after the discontinuation of the offending drug, leaving postinflammatory hyperpigmentation (",
"    <a class=\"graphic graphic_picture graphicRef83771 \" href=\"UTD.htm?39/31/40437\">",
"     picture 5",
"    </a>",
"    ). Occasionally, the eruption disappears or recurs intermittently despite continuation of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29641623\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29641632\">",
"    <span class=\"h2\">",
"     Histopathologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologically, lichenoid drug eruption is an interface dermatitis. Lichenoid interface dermatitis is a nonspecific reaction pattern occurring in idiopathic lichen planus and other lichenoid eruptions (eg, lichenoid purpura, cutaneous graft-versus-host disease, pityriasis lichenoides chronica, discoid lupus erythematosus, fixed drug eruption) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/5\">",
"     5",
"    </a>",
"    ]. Lichenoid interface dermatitis also may be found in some cases of maculopapular drug reactions.",
"   </p>",
"   <p>",
"    Major pathologic findings seen in both lichenoid drug eruption and lichen planus include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Damage of basal epidermal keratinocytes with multiple apoptotic cells (colloid or Civatte bodies)",
"     </li>",
"     <li>",
"      A band-like lymphocytic infiltrate in the papillary dermis that obscures the dermoepidermal junction",
"     </li>",
"     <li>",
"      Pigmentary incontinence with dermal melanophages",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Findings that are more typical of lichenoid drug eruption than lichen planus include (",
"    <a class=\"graphic graphic_table graphicRef83936 \" href=\"UTD.htm?20/14/20715\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef83937 \" href=\"UTD.htm?6/22/6504\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Focal parakeratosis",
"     </li>",
"     <li>",
"      Focal interruption of the granular layer",
"     </li>",
"     <li>",
"      Cytoid bodies in the cornified and granular layers",
"     </li>",
"     <li>",
"      Presence of eosinophils",
"     </li>",
"     <li>",
"      Exocytosis of lymphoid cells into the upper epidermis",
"     </li>",
"     <li>",
"      Deeper perivascular infiltrate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These features are seen more often in non-photodistributed lesions. Photodistributed lesions are usually indistinguishable from idiopathic lichen planus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29641639\">",
"    <span class=\"h2\">",
"     Direct immunofluorescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct immunofluorescence shows globular deposits of IgM and occasionally IgG and IgA at the dermoepidermal junction and in the lower epidermis. Shaggy deposition of fibrinogen at the dermoepidermal junction is also seen. As in lichen planus, marked cytoid body staining may be present in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29641646\">",
"    <span class=\"h2\">",
"     Immunohistochemical studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunohistochemical studies show that the majority of the cells in the infiltrate at the dermoepidermal interface are CD4 and autoreactive CD8 effector T cells. Immunohistochemical staining is not routinely performed for the diagnosis of lichenoid skin eruption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29641653\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of lichenoid drug eruption is based upon a combination of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Clinical features",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Symmetric eruption of flat-topped, erythematous or violaceous papules, often grouped and confluent, resembling lichen planus on the trunk and extremities (",
"      <a class=\"graphic graphic_picture graphicRef83767 graphicRef83768 graphicRef83769 \" href=\"UTD.htm?28/38/29290\">",
"       picture 1A-B, 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29641602\">",
"       'Skin lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Evaluation of a skin biopsy",
"      </strong>",
"      &ndash; Histologic findings of interface dermatitis with a band-like lymphocytic infiltrate and other histopathologic features more characteristic of lichenoid drug eruption (",
"      <a class=\"graphic graphic_picture graphicRef83937 \" href=\"UTD.htm?6/22/6504\">",
"       picture 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29641632\">",
"       'Histopathologic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Medication history",
"      </strong>",
"      &ndash; Evidence of temporal relationship between drug intake and development of skin lesions. The assessment of a temporal relationship between drug intake and onset of the eruption may be difficult because of the wide variability in the latency time, particularly in patients on multiple medications. (See",
"      <a class=\"local\" href=\"#H29641572\">",
"       'Latency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Clinical course",
"      </strong>",
"      &ndash; Resolution upon drug withdrawal and recurrence upon rechallenge. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patch testing with the patient&rsquo;s drugs has been used to try to determine the offending agent in patients with various types of cutaneous drug reactions and in patients with oral lichen planus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. However, patch testing is not routinely performed in patients with suspected lichenoid drug eruptions because false negative results are frequent. In small observational studies only 30 to 50 percent of patients with cutaneous drug reactions had positive or clinically relevant patch tests [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29641676\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that should be considered in the differential diagnosis of lichenoid drug eruption include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Lichen planus",
"      </strong>",
"      &ndash; The cutaneous lesions of lichen planus are shiny, flat, polygonal, violaceous papules (",
"      <a class=\"graphic graphic_picture graphicRef70518 graphicRef58361 graphicRef50632 \" href=\"UTD.htm?20/63/21498\">",
"       picture 2B, 2E-F",
"      </a>",
"      ); the morphology is similar to that of lichenoid drug eruption. However, in lichen planus, fine, white lacelike patterns known as Wickham striae are present over the surface of many papules (",
"      <a class=\"graphic graphic_picture graphicRef61523 \" href=\"UTD.htm?27/20/27968\">",
"       picture 3",
"      </a>",
"      ). Moreover, the lesions of idiopathic lichen planus are typically distributed symmetrically over the extremities and tend to involve the flexural areas of wrists, arms, and legs (",
"      <a class=\"graphic graphic_picture graphicRef76383 \" href=\"UTD.htm?28/42/29346\">",
"       picture 2A",
"      </a>",
"      ), whereas in lichenoid drug eruption the lesions typically occur on the trunk and extensor surfaces. Oral involvement is common in lichen planus and less so in lichenoid drug eruption. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=see_link&amp;anchor=H6#H6\">",
"       \"Lichen planus\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The histopathologic differential diagnosis of lichen planus and lichenoid drug eruption is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef83936 \" href=\"UTD.htm?20/14/20715\">",
"     table 2",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Lupus erythematosus",
"      </strong>",
"      &ndash; On histology, a lichenoid interface dermatitis may be seen in some cases of chronic cutaneous lupus erythematosus. In contrast to lichenoid drug eruption, lesions of lupus erythematosus show a moderately dense perivascular and periappendageal lymphocytic infiltrate in the papillary and reticular dermis, with abundant mucin deposits in the latter. There is focal or continuous epidermal thinning, smudged appearance of the dermoepidermal junction with vacuolar degeneration of basal cells, individual necrotic keratinocytes, and a thickened basal membrane zone. Direct immunofluorescence reveals a band-like deposition of IgG and IgM along the basement membrane zone in most cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Giant cell lichenoid dermatitis",
"      </strong>",
"      &ndash; Giant cell lichenoid dermatitis is a rare condition considered an unusual variant of lichenoid drug eruption or a manifestation of sarcoidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/42\">",
"       42",
"      </a>",
"      ]. Histopathologic findings include focal vacuolar alteration of the basal layer with cytoid bodies, dermal and intraepidermal multinucleated giant cells, and a chronic inflammatory infiltrate consisting of lymphocytes, eosinophils, plasma cells, and macrophages.",
"     </li>",
"     <li>",
"      <strong>",
"       Keratosis lichenoides chronica",
"      </strong>",
"      &ndash; Keratosis lichenoides chronica is a rare disorder characterized by violaceous, tiny papules centered on hair infundibula and sweat ducts and arranged in a linear and reticulate pattern [",
"      <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. Histologically, there is a lichenoid infiltrate with focal epidermal acanthosis and atrophy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29641683\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38715886\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lichenoid drug eruptions generally resolve spontaneously a few weeks to a few months after the discontinuation of the offending drug [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/6,45\">",
"     6,45",
"    </a>",
"    ]. However, treatment may be warranted in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients who cannot discontinue the offending drug",
"     </li>",
"     <li>",
"      Prolonged disease (ie, persistent lesions several months after discontinuation of the drug)",
"     </li>",
"     <li>",
"      Extensive disease (eg, involving the trunk and extremities)",
"     </li>",
"     <li>",
"      Symptoms (eg, pruritus)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64668815\">",
"    <span class=\"h2\">",
"     Cutaneous eruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options include topical or systemic corticosteroids and oral retinoids.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with symptomatic disease involving a limited skin area (eg, the extremities), we suggest topical corticosteroids rather than oral corticosteroids. We generally use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      propionate 0.05% or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/56/30596?source=see_link\">",
"       fluocinonide",
"      </a>",
"      0.05% ointment or cream twice daily for two to four weeks.",
"     </li>",
"     <li>",
"      For patients with extensive, symptomatic disease, we suggest oral corticosteroids rather than topical corticosteroids or oral retinoids. We generally use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      30 to 60 mg per day for two to six weeks. Prednisone is then tapered over the next two to six weeks.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"       Acitretin",
"      </a>",
"      25 to 35 mg per day for six to twelve weeks is an alternative for patients in whom systemic corticosteroids are contraindicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of topical corticosteroids, systemic corticosteroids, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    for lichenoid drug eruption has not been evaluated in randomized trials. Their use is based upon clinical experience and limited evidence of efficacy from a few small clinical studies in patients with idiopathic lichen planus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=see_link&amp;anchor=H9#H9\">",
"     \"Lichen planus\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64668843\">",
"    <span class=\"h2\">",
"     Oral eruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reticular form of oral lichenoid drug eruption is generally asymptomatic and does not require treatment. Topical or oral corticosteroids are used for the treatment of the erosive form to reduce pain and discomfort and hasten healing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with oral erosive lichenoid drug eruption, we suggest topical corticosteroids as first line treatment. We typically use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      propionate 0.05% ointment two or three times per day for four to eight weeks.",
"     </li>",
"     <li>",
"      For patients with oral erosive lichenoid drug eruption that does not respond to topical corticosteroids, we suggest oral corticosteroids. We generally use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of 30 to 60 mg per day for two to six weeks. Prednisone is then tapered over the next two to six weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of topical and oral corticosteroids for the treatment of oral erosive lichenoid drug eruption has not been evaluated in randomized trials. Their use is based upon clinical experience and limited evidence of efficacy from randomized trials in idiopathic oral lichen planus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3848/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=see_link\">",
"     \"Lichen planus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26361?source=see_link\">",
"     \"Oral lichen planus: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29641690\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lichenoid drug eruption, also called drug-induced lichen planus, is an uncommon cutaneous adverse effect of several drugs. (See",
"      <a class=\"local\" href=\"#H29641535\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The drugs most frequently reported are ACE inhibitors, thiazide diuretics, antimalarials, beta blockers, gold salts, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef83762 \" href=\"UTD.htm?1/20/1357\">",
"       table 1",
"      </a>",
"      ). The latency period between the drug initiation and the appearance of the eruption varies from months to a year or more. (See",
"      <a class=\"local\" href=\"#H29641565\">",
"       'Medications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29641572\">",
"       'Latency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lichenoid drug eruption manifests with a symmetric eruption of erythematous or violaceous, flat-topped polygonal papules, often grouped and confluent. They have eczematous or psoriasiform morphology with marked desquamation. The eruption involves the trunk and extensor aspects of the extremities (",
"      <a class=\"graphic graphic_picture graphicRef83767 graphicRef83768 graphicRef83769 graphicRef59258 \" href=\"UTD.htm?39/50/40746\">",
"       picture 1A-B, 2C-D",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29641602\">",
"       'Skin lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of lichenoid drug eruption is based upon a combination of the following findings (see",
"      <a class=\"local\" href=\"#H29641653\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Clinical findings of a symmetric eruption of flat-topped, erythematous or violaceous papules resembling lichen planus on the trunk and extremities (",
"      <a class=\"graphic graphic_picture graphicRef83767 graphicRef83768 graphicRef83769 \" href=\"UTD.htm?28/38/29290\">",
"       picture 1A-B, 2C",
"      </a>",
"      ) &nbsp;",
"     </li>",
"     <li>",
"      Histologic findings of interface dermatitis with a band-like lymphocytic infiltrate (",
"      <a class=\"graphic graphic_picture graphicRef83937 \" href=\"UTD.htm?6/22/6504\">",
"       picture 6",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H29641632\">",
"       'Histopathologic findings'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Temporal relationship between drug intake and development of skin lesions",
"     </li>",
"     <li>",
"      Resolution upon drug withdrawal and recurrence upon rechallenge &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lichenoid drug eruptions generally resolve spontaneously a few weeks to a few months after the discontinuation of the offending drug. Treatment may be warranted in patients who cannot discontinue the offending drug or have symptomatic or extensive disease. (See",
"      <a class=\"local\" href=\"#H38715886\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For patients with symptomatic disease involving a limited skin area (eg, the extremities), we suggest topical corticosteroids rather than oral corticosteroids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We generally use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      propionate 0.05% or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/56/30596?source=see_link\">",
"       fluocinonide",
"      </a>",
"      0.05% ointment or cream twice daily for two to four weeks. (See",
"      <a class=\"local\" href=\"#H64668815\">",
"       'Cutaneous eruption'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with extensive, symptomatic disease, we suggest oral corticosteroids rather than topical corticosteroids or oral retinoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We generally use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      30 to 60 mg per day for two to six weeks. Prednisone is then tapered over the next two to six weeks.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"       Acitretin",
"      </a>",
"      25 to 35 mg per day for six to twelve weeks is an alternative for patients in whom systemic corticosteroids are contraindicated. (See",
"      <a class=\"local\" href=\"#H64668815\">",
"       'Cutaneous eruption'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patient with oral erosive lichenoid drug eruption, we suggest topical corticosteroids as first line treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We typically use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      propionate 0.05% ointment two or three times per day for four to eight weeks. (See",
"      <a class=\"local\" href=\"#H64668843\">",
"       'Oral eruption'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with oral erosive lichenoid drug eruption that does not respond to topical corticosteroids, we suggest oral corticosteroids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We generally use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of 30 to 60 mg per day for two to six weeks. Prednisone is then tapered over the next two to six weeks. (See",
"      <a class=\"local\" href=\"#H64668843\">",
"       'Oral eruption'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/1\">",
"      Fox GN, Harrell CC, Mehregan DR. Extensive lichenoid drug eruption due to glyburide: a case report and review of the literature. Cutis 2005; 76:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/2\">",
"      Antiga E, Melani L, Cardinali C, et al. A case of lichenoid drug eruption associated with sildenafil citratus. J Dermatol 2005; 32:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/3\">",
"      Brauer J, Votava HJ, Meehan S, Soter NA. Lichenoid drug eruption. Dermatol Online J 2009; 15:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/4\">",
"      Asarch A, Gottlieb AB, Lee J, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 2009; 61:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/5\">",
"      Sontheimer RD. Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives. J Invest Dermatol 2009; 129:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/6\">",
"      Halevy S, Shai A. Lichenoid drug eruptions. J Am Acad Dermatol 1993; 29:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/7\">",
"      West AJ, Berger TG, LeBoit PE. A comparative histopathologic study of photodistributed and nonphotodistributed lichenoid drug eruptions. J Am Acad Dermatol 1990; 23:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/8\">",
"      Lage D, Juliano PB, Metze K, et al. Lichen planus and lichenoid drug-induced eruption: a histological and immunohistochemical study. Int J Dermatol 2012; 51:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/9\">",
"      Yawalkar N, Pichler WJ. [Mechanisms of cutaneous drug reactions]. J Dtsch Dermatol Ges 2004; 2:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/10\">",
"      Sugerman PB, Satterwhite K, Bigby M. Autocytotoxic T-cell clones in lichen planus. Br J Dermatol 2000; 142:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/11\">",
"      Yawalkar N, Pichler WJ. Immunohistology of drug-induced exanthema: clues to pathogenesis. Curr Opin Allergy Clin Immunol 2001; 1:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/12\">",
"      Yawalkar N, Egli F, Hari Y, et al. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000; 30:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/13\">",
"      Yawalkar N, Shrikhande M, Hari Y, et al. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000; 106:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/14\">",
"      Meller S, Gilliet M, Homey B. Chemokines in the pathogenesis of lichenoid tissue reactions. J Invest Dermatol 2009; 129:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/15\">",
"      Wenzel J, Scheler M, Proelss J, et al. Type I interferon-associated cytotoxic inflammation in lichen planus. J Cutan Pathol 2006; 33:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/16\">",
"      Erdem MT, Gulec AI, Kiziltunc A, et al. Increased serum levels of tumor necrosis factor alpha in lichen planus. Dermatology 2003; 207:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/17\">",
"      Akasu R, From L, Kahn HJ. Lymphocyte and macrophage subsets in active and inactive lesions of lichen planus. Am J Dermatopathol 1993; 15:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/18\">",
"      Fiorentino DF. The Yin and Yang of TNF-{alpha} inhibition. Arch Dermatol 2007; 143:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/19\">",
"      Teraki Y, Shiohara T. Spontaneous tolerance to terbinafine-induced lichenoid drug eruption. Dermatology 2004; 208:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/20\">",
"      Bong JL, Lucke TW, Douglas WS. Lichenoid drug eruption with proton pump inhibitors. BMJ 2000; 320:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/21\">",
"      Van den Haute V, Antoine JL, Lachapelle JM. Histopathological discriminant criteria between lichenoid drug eruption and idiopathic lichen planus: retrospective study on selected samples. Dermatologica 1989; 179:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/22\">",
"      De Simone C, Caldarola G, D'Agostino M, et al. Lichenoid reaction induced by adalimumab. J Eur Acad Dermatol Venereol 2008; 22:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/23\">",
"      Vergara G, Silvestre JF, Betlloch I, et al. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 2002; 138:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/24\">",
"      Woo V, Bonks J, Borukhova L, Zegarelli D. Oral lichenoid drug eruption: a report of a pediatric case and review of the literature. Pediatr Dermatol 2009; 26:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/25\">",
"      Powell FC, Rogers RS 3rd, Dickson ER. Primary biliary cirrhosis and lichen planus. J Am Acad Dermatol 1983; 9:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/26\">",
"      Rotstein E, Rotstein H. Drug eruptions with lichenoid histology produced by captopril. Australas J Dermatol 1989; 30:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/27\">",
"      Bauer F. Quinacrine hydrochloride drug eruption (tropical lichenoid dermatitis). Its early and late sequelae and its malignant potential: a review. J Am Acad Dermatol 1981; 4:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/28\">",
"      Garcovich S, Manco S, Zampetti A, et al. Onset of lichen planopilaris during treatment with etanercept. Br J Dermatol 2008; 158:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/29\">",
"      Wahiduzzaman M, Pubalan M. Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review. Dermatol Online J 2008; 14:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/30\">",
"      HARBER LC, LASHINSKY AM, BAER RL. Photosensitivity due to chlorothiazide and hydrochlorothiazide. N Engl J Med 1959; 261:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/31\">",
"      Kubo Y, Fukumoto D, Ishigami T, et al. Diltiazem-associated photodistributed hyperpigmentation: report of two Japanese cases and published work review. J Dermatol 2010; 37:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/32\">",
"      Johnston GA. Thiazide-induced lichenoid photosensitivity. Clin Exp Dermatol 2002; 27:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/33\">",
"      Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf 2007; 6:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/34\">",
"      Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002; 25:345.",
"     </a>",
"    </li>",
"    <li>",
"     Bork K. Lichenoid eruptions. In: Cutaneous Side Effects of Drugs, Bork K (Ed), WB Saunders, Philadelphia 1988. p.170.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/36\">",
"      Anderson TE. Lichen planus following quinidine therapy. Br J Dermatol 1967; 79:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/37\">",
"      Seehafer JR, Rogers RS 3rd, Fleming CR, Dickson ER. Lichen planus-like lesions caused by penicillamine in primary biliary cirrhosis. Arch Dermatol 1981; 117:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/38\">",
"      Oliver GF, Winkelmann RK, Muller SA. Lichenoid dermatitis: a clinicopathologic and immunopathologic review of sixty-two cases. J Am Acad Dermatol 1989; 21:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/39\">",
"      Barbaud A, Gon&ccedil;alo M, Bruynzeel D, et al. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001; 45:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/40\">",
"      Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 2005; 209:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/41\">",
"      Lomaga MA, Polak S, Grushka M, Walsh S. Results of patch testing in patients diagnosed with oral lichen planus. J Cutan Med Surg 2009; 13:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/42\">",
"      Khelifa-Hamdani E, Touati-Serraj M, Perriard J, et al. Giant cell lichenoid dermatitis in a patient with baboon syndrome. J Cutan Pathol 2008; 35 Suppl 1:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/43\">",
"      B&ouml;er A. Keratosis lichenoides chronica: proposal of a concept. Am J Dermatopathol 2006; 28:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/44\">",
"      Konstantinov KN, S&oslash;ndergaard J, Izuno G, Obreshkova E. Keratosis lichenoides chronica. J Am Acad Dermatol 1998; 38:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/45\">",
"      Ellgehausen P, Elsner P, Burg G. Drug-induced lichen planus. Clin Dermatol 1998; 16:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/46\">",
"      Cribier B, Frances C, Chosidow O. Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol 1998; 134:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/47\">",
"      Laurberg G, Geiger JM, Hjorth N, et al. Treatment of lichen planus with acitretin. A double-blind, placebo-controlled study in 65 patients. J Am Acad Dermatol 1991; 24:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/48\">",
"      Le Cleach L, Chosidow O. Clinical practice. Lichen planus. N Engl J Med 2012; 366:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/49\">",
"      Cheng S, Kirtschig G, Cooper S, et al. Interventions for erosive lichen planus affecting mucosal sites. Cochrane Database Syst Rev 2012; 2:CD008092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3848/abstract/50\">",
"      Thongprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. Cochrane Database Syst Rev 2011; :CD001168.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15763 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-7920B88E07-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_48_3848=[""].join("\n");
var outline_f3_48_3848=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29641690\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29641535\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H286117\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29641549\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29641558\">",
"      Immunologic mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29641565\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29641572\">",
"      Latency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29641579\">",
"      Contribution of UV irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29641593\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29641602\">",
"      Skin lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29641609\">",
"      Oral lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H71523368\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29641623\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29641632\">",
"      Histopathologic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29641639\">",
"      Direct immunofluorescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29641646\">",
"      Immunohistochemical studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29641653\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29641676\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29641683\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38715886\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64668815\">",
"      Cutaneous eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64668843\">",
"      Oral eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29641690\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15763\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15763|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/37/22100\" title=\"picture 1A\">",
"      Lichenoid drug eruption 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/25/24977\" title=\"picture 1B\">",
"      Lichenoid drug eruption 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/42/29346\" title=\"picture 2A\">",
"      Lichen planus wrists fair skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/50/805\" title=\"picture 2B\">",
"      Generalized lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/50/37670\" title=\"picture 2C\">",
"      Lichenoid drug eruption hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/33/35348\" title=\"picture 2D\">",
"      Lichenoid drug eruption hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/38/24160\" title=\"picture 2E\">",
"      Lichen planus arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/11/22709\" title=\"picture 2F\">",
"      Lichen planus hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/20/27968\" title=\"picture 3\">",
"      Wickhams striae on plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/8/9349\" title=\"picture 4\">",
"      Lichenoid drug eruption oral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/31/40437\" title=\"picture 5\">",
"      Lichenoid drug eruption hyperpigmentation 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/22/6504\" title=\"picture 6\">",
"      Lichenoid interface dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15763|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/20/1357\" title=\"table 1\">",
"      Drugs causing lichenoid eruptions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/14/20715\" title=\"table 2\">",
"      Lichenoid drug eruption histology differential",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42951?source=related_link\">",
"      Acute generalized exanthematous pustulosis (AGEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43929?source=related_link\">",
"      Drug reaction with eosinophilia and systemic symptoms (DRESS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24360?source=related_link\">",
"      Exanthematous (morbilliform) drug eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/50/9000?source=related_link\">",
"      Fixed drug eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=related_link\">",
"      Lichen planus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26361?source=related_link\">",
"      Oral lichen planus: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_48_3849="Hamilton Rating Scale - page 1";
var content_f3_48_3849=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F72220%7EPSYCH%2F60363%7EPSYCH%2F73164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F72220%7EPSYCH%2F60363%7EPSYCH%2F73164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 611px\">",
"   <div class=\"ttl\">",
"    Hamilton Rating Scale for Depression, page 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 591px; height: 651px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Hamilton, M. A rating scale for depression. J Neurosurg Psychiatry 1960; 23:56.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Hamilton Rating Scale for Depression, page 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 685px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Hamilton, M. A rating scale for depression. J Neurosurg Psychiatry 1960; 23:56.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Hamilton Rating Scale for Depression, page 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 760px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Hamilton, M. A rating scale for depression. J Neurosurg Psychiatry 1960; 23:56.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_48_3849=[""].join("\n");
var outline_f3_48_3849=null;
var title_f3_48_3850="Subclinical hypothyroidism";
var content_f3_48_3850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Subclinical hypothyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/48/3850/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/48/3850/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/48/3850/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/48/3850/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/48/3850/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/48/3850/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/48/3850/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclinical hypothyroidism is defined biochemically as a normal serum free thyroxine (T4) concentration in the presence of an elevated serum thyrotropin (TSH) concentration. Some patients with subclinical hypothyroidism may have vague, non-specific symptoms suggestive of hypothyroidism, but attempts to identify patients clinically have not been successful [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Thus, this disorder can only be diagnosed on the basis of laboratory test results.",
"   </p>",
"   <p>",
"    This topic will review the diagnosis and management of subclinical hypothyroidism. The clinical manifestations, diagnosis, and management of overt hypothyroidism are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link\">",
"     \"Laboratory assessment of thyroid function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In population-based studies, the prevalence of subclinical hypothyroidism ranges from 4 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/1,3-7\">",
"     1,3-7",
"    </a>",
"    ]. In the United States National Health and Examination Survey (NHANES III), which excluded subjects with known thyroid disease, 4.3 percent of 16,533 people had subclinical hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/8\">",
"     8",
"    </a>",
"    ]. The prevalence rises with age, is higher in females than males, and is lower in blacks than in whites [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. However, the prevalence is determined by the upper limit of normal for serum TSH. If the upper limit of normal rises with age, as appears to be the case, then the prevalence may not be as high as has been previously thought. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In Europe, where iodine intake is variable, subclinical hypothyroidism is more prevalent in areas of iodine sufficiency. In one study, the prevalence of subclinical hypothyroidism ranged from 4.2 percent in iodine-deficient areas to 23.9 percent in an area of abundant iodine intake, despite a similar prevalence of patients with high serum concentrations of anti-thyroid peroxidase antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of subclinical hypothyroidism are the same as those of overt hypothyroidism (",
"    <a class=\"graphic graphic_table graphicRef73266 \" href=\"UTD.htm?36/62/37867\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"     \"Disorders that cause hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients have chronic autoimmune (Hashimoto's) thyroiditis with high serum concentrations of antithyroid peroxidase (anti-TPO antibodies, formerly called antithyroid microsomal) antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/10\">",
"     10",
"    </a>",
"    ]. Other major causes include prior ablative or antithyroid drug therapy for hyperthyroidism caused by Graves' disease; prior partial thyroidectomy; external radiation therapy in patients with Hodgkin lymphoma, leukemia, or brain tumors; inadequate T4 replacement therapy for overt hypothyroidism; and drugs impairing thyroid function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although subclinical hypothyroidism is a common disorder, the value of screening for it at a routine examination when there is no relevant complaint or finding is controversial. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of subclinical hypothyroidism is based upon biochemical testing alone. As noted above, it is defined as a normal serum free T4 and an elevated TSH [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. It may occur in the presence or absence of mild symptoms of hypothyroidism. Most patients have serum TSH levels &lt;10",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    and are asymptomatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most circumstances, the initial screening test for thyroid disease is the serum TSH. If the serum TSH concentration is elevated, the TSH measurement should be repeated along with a serum free T4 to make the diagnosis of subclinical hypothyroidism. Because the serum TSH concentration can be transiently elevated, a serum TSH measurement should be repeated after one to three months to confirm the diagnosis. However, in circumstances where there is a strong indication for T4 therapy, such as pregnancy or infertility, T4 replacement should be initiated if the serum TSH is elevated when repeated along with the serum free T4. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link&amp;anchor=H57693666#H57693666\">",
"     \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\", section on 'Candidates for treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An elevated serum TSH is defined as a TSH concentration above the upper limit of the normal TSH reference range, which is typically 4 to 5",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    in most laboratories. Presently, there is considerable controversy over the appropriate upper limit of normal for serum TSH. Some experts have suggested that the true upper limit is only 2.5 or 3",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    in healthy individuals without thyroid disease, while others argue that the serum TSH distribution shifts towards higher values with age, independent of the presence of antithyroid antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/12\">",
"     12",
"    </a>",
"    ]. In this case, the upper limit of normal could be as high as 6 to 8",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    in healthy octogenarians. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link&amp;anchor=H3#H3\">",
"     \"Laboratory assessment of thyroid function\", section on 'Serum TSH concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several causes of a high serum TSH concentration that do not properly fit the definition of subclinical hypothyroidism. These include the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the period of recovery from nonthyroidal illness, where a transiently elevated serum TSH is seen after a period of TSH suppression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"       \"Thyroid function in nonthyroidal illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Following the hyperthyroid phase of subacute, painless, or postpartum thyroiditis, where mild hypothyroidism is usually, but not always, transient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=see_link\">",
"       \"Overview of thyroiditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Assay variability.",
"     </li>",
"     <li>",
"      The presence of heterophilic antibodies can interfere with TSH measurements in immunometric assays. These human anti-mouse gamma globulins can bridge the two mouse monoclonal antibodies (solid phase antibody and signal antibody) and cause spuriously elevated readings for TSH [",
"      <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/13\">",
"       13",
"      </a>",
"      ]. Rarely, heterophilic antibodies block binding of one of the mouse monoclonal antibodies to TSH and result in spuriously low readings for TSH. Non-linearity with dilution suggests interference. Addition of nonimmune homologous mouse immunoglobulins has reduced this type of assay interference. Commercial assays exist for detecting human anti-mouse antibodies (HAMA).",
"     </li>",
"     <li>",
"      Rheumatoid factors may cause similar interference in immunometric assays [",
"      <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autoantibodies to TSH have also been described which create TSH-anti-TSH IgG complexes, also called macro-TSH, which lacks biologic activity but may be immunoreactive, and cause spuriously high TSH values (often &gt;100",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      in euthyroid (normal free T4 and T3 levels) individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/14-16\">",
"       14-16",
"      </a>",
"      ]. Autoantibodies to TSH can be detected by removal of the IgG-TSH complexes with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"       polyethylene glycol",
"      </a>",
"      or protein A or G, then repeating the assay on the immunosubtracted sera [",
"      <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Untreated adrenal insufficiency.",
"     </li>",
"     <li>",
"      TSH-producing pituitary adenomas, resistance to thyroid hormone, and rare mutations of the TSH receptor. In patients with TSH-producing pituitary adenomas or resistance to thyroid hormone, the elevated TSH is associated with elevated serum free T4",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      T3 concentrations. In contrast, patients with subclinical hypothyroidism have normal free T4 levels. Patients with resistance to TSH secondary to alterations in the TSH receptor have high serum TSH concentrations and normal or low serum free T4 and T3 concentrations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/20/327?source=see_link\">",
"       \"Thyrotropin (TSH)-secreting pituitary adenomas\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1626?source=see_link\">",
"       \"Reduced sensitivity to thyroid hormone\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16518?source=see_link\">",
"       \"Resistance to thyrotropin and thyrotropin-releasing hormone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central hypothyroidism, where up to 25 percent of patients have a mildly elevated serum TSH (up to about 10",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      and a low or low-normal free T4. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link\">",
"       \"Central hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with subclinical hypothyroidism have mild non-specific symptoms of hypothyroidism, such as fatigue and constipation. Thus, patients with subclinical hypothyroidism should be questioned about symptoms of hypothyroidism, in addition to past treatment for hyperthyroidism, a history of overt hypothyroidism, and use of medications that may impair thyroid hormone absorption or function (",
"    <a class=\"graphic graphic_table graphicRef50439 \" href=\"UTD.htm?21/19/21820\">",
"     table 2",
"    </a>",
"    ). In addition, they should be examined for the presence of thyroid gland enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not routinely measure antithyroid peroxidase antibodies in patients with subclinical hypothyroidism. However, the presence of antibodies may be useful in making a decision to treat with T4 or to monitor, and thus may be useful in patients when the decision to treat or to monitor is not obvious.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF SUBCLINICAL HYPOTHYROIDISM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Progression to overt hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substantial proportion of patients with subclinical hypothyroidism eventually develop overt hypothyroidism. In prospective studies with nearly 10 to 20 years of follow-up, the cumulative incidence of overt hypothyroidism ranges from 33 to 55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of progression is related to the initial serum TSH concentration (higher with TSH values &gt;12 to 15",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    and the presence of antithyroid peroxidase antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/19,22,23\">",
"     19,22,23",
"    </a>",
"    ]. In a study in which more than 1700 subjects were followed for 20 years, for example, women with both high serum TSH and high thyroid antibody concentrations developed hypothyroidism at a rate of 4.3 percent per year (cumulative incidence 55 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/20\">",
"     20",
"    </a>",
"    ]. In another study in which 82 women were observed for 9.2 years, the cumulative incidence of overt hypothyroidism was zero percent for subjects with initial TSH concentrations of 4 to 6",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The underlying disease also may be a determinant of the risk of overt hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients who have autoimmune thyroid disease or received radioiodine therapy or high-dose external radiotherapy are likely to progress to overt hypothyroidism. In contrast, subclinical hypothyroidism is likely to persist in those who have had thyroid surgery for indications other than hyperthyroidism, or in those who received external radiotherapy during childhood.",
"   </p>",
"   <p>",
"    Spontaneous recovery has also been described in patients with subclinical hypothyroidism, although the frequency of this phenomenon is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/19,23-25\">",
"     19,23-25",
"    </a>",
"    ]. In a study of 422,242 persons without known thyroid disease, serum TSH was elevated (5.5 to &le;10",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    in 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/25\">",
"     25",
"    </a>",
"    ]. During the five-year follow-up period, TSH levels became normal in the absence of treatment in 62 percent of patients. Normalization of serum TSH concentrations is more likely to occur in patients with negative antithyroid antibodies, serum TSH levels &lt;10",
"    <span class=\"nowrap\">",
"     mU/I,",
"    </span>",
"    and within the first two years after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overt hypothyroidism may be associated with an increased risk of cardiovascular disease (CVD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3046?source=see_link\">",
"     \"Cardiovascular effects of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with subclinical hypothyroidism, the data are conflicting, likely related to differences in the patient populations and study designs. Some [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/26-30\">",
"     26-30",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/31-33\">",
"     31-33",
"    </a>",
"    ], observational studies report an increased risk of coronary heart disease in subjects with subclinical hypothyroidism. A meta-analysis of patient level data from seven prospective cohort studies (25,977 participants, 2020 with subclinical hypothyroidism) showed a significant trend of increased risk of coronary heart disease (CHD) events (nonfatal myocardial infarction, CHD death, hospitalization for angina or coronary revascularization) at higher serum TSH concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/34\">",
"     34",
"    </a>",
"    ]. Compared with euthyroid subjects, participants with TSH &ge;10",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    had a significant increase in CHD events (38.4 versus 20.3",
"    <span class=\"nowrap\">",
"     events/1000",
"    </span>",
"    person years, HR 1.89, 95% CI 1.28-2.80). In contrast, minimal TSH elevations (4.5 to 6.9",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    were not associated with an increased risk (HR 1.00, 95% CI 0.96-1.43). The risk estimates did not differ according to age, gender, or presence of preexisting CVD.",
"   </p>",
"   <p>",
"    In a pooled analysis of patient level data from six prospective cohort studies (25,390 participants, 2068 with subclinical hypothyroidism), there was also a significant trend for increased risk of heart failure events at higher TSH concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/35\">",
"     35",
"    </a>",
"    ]. Compared with euthyroid controls, participants with a TSH between 10 and 19.9",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    had a significant increase in heart failure (40 events in 224 participants [17.9 percent] versus 1762 events in 22,674 controls [7.8 percent], HR 1.86, 95% CI 1.27-2.72) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/35\">",
"     35",
"    </a>",
"    ]. The increased risk of heart failure in those with a serum TSH between 7.0 and 9.9",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    was not statistically significant (54 events in 422 participants [12.8 percent], HR 1.65, 95% CI 0.84-3.23), and minimal TSH elevations (4.5 to 6.9",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    were not associated with an increased risk (HR 1.01, 95% CI 0.81-1.26).",
"   </p>",
"   <p>",
"    Some, but not all, studies show an association between elevated TSH and total and LDL cholesterol concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/10\">",
"     10",
"    </a>",
"    ]. In one of the largest cross-sectional studies to date (25,862 participants, median age 56 years), subjects with modest elevations of serum TSH (between 5.1 and 10",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    had significantly higher mean total cholesterol concentrations than those who were euthyroid (223 versus 216",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.6 versus 5.8",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/6\">",
"     6",
"    </a>",
"    ]. However, cholesterol levels were not adjusted for age. In addition, it is not known whether this difference is clinically important with regard to CHD risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28550?source=see_link&amp;anchor=H7#H7\">",
"     \"Lipid abnormalities in thyroid disease\", section on 'Subclinical hypothyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, subclinical hypothyroidism has been associated with an increase in a number of other cardiovascular risk factors and surrogate cardiovascular endpoints, including markers of inflammation, vascular reactivity, endothelial function, and carotid intima media thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/36-41\">",
"     36-41",
"    </a>",
"    ]. Some patients with subclinical hypothyroidism also have diastolic dysfunction and increased peripheral vascular resistance, as noted in patients with overt hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/42\">",
"     42",
"    </a>",
"    ]. In contrast, another study found no abnormalities in left ventricular mass or function in patients with serum TSH concentrations between 3.5 and 10",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    compared to those with normal TSH [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3046?source=see_link\">",
"     \"Cardiovascular effects of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/28,29,44-46\">",
"     28,29,44-46",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/32,47-49\">",
"     32,47-49",
"    </a>",
"    ], studies, patients with subclinical hypothyroidism have an increased risk of cardiovascular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    all-cause mortality. In a meta-analysis of patient level data from 11 prospective cohort studies, the risk of cardiovascular mortality, but not all-cause mortality, increased with higher concentrations of TSH and was significantly increased in participants with TSH concentrations &ge;10",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    (HR 1.58, 95% CI 1.10-2.27) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/34\">",
"     34",
"    </a>",
"    ]. In contrast, minimal elevations of TSH (4.5 to 6.9",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    were not associated with cardiovascular or all-cause mortality. In one prospective study included in the meta-analysis, elderly individuals (&gt;85 years) in the Netherlands with untreated subclinical hypothyroidism actually had a lower rate of cardiovascular and all-cause mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/47\">",
"     47",
"    </a>",
"    ]. In a prospective cohort study published after the meta-analysis, elderly individuals in the United States with untreated subclinical hypothyroidism had neither increased nor decreased mortality over a median follow-up period of five years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis of and screening for hypothyroidism\", section on 'Effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415078\">",
"    <span class=\"h2\">",
"     Non-alcoholic fatty liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a cross-sectional study, non-alcoholic fatty liver disease (NAFLD) was correlated with serum TSH levels. Thirty and 36 percent of individuals with subclinical or overt hypothyroidism, respectively, had typical ultrasonographic findings of NAFLD (versus 20 percent of controls) while 20 and 26 percent of individuals with subclinical or overt hypothyroidism had abnormal liver enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neuropsychiatric symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports suggest that subclinical hypothyroidism is associated with neuropsychiatric diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. However, other studies (including a large study of primary care patients in England that failed to demonstrate an association of subclinical hypothyroidism with depression, anxiety, or cognitive dysfunction) do not support this observation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/10,47,56-58\">",
"     10,47,56-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Potential consequences",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In three studies, increasing serum TSH concentrations within the normal range were associated with a modest increase in body weight [",
"      <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/59-61\">",
"       59-61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3418?source=see_link&amp;anchor=H30#H30\">",
"       \"Etiology and natural history of obesity\", section on 'Hypothyroidism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In one study, 21 of 33 patients (64 percent) with subclinical hypothyroidism had a higher frequency of neuromuscular symptoms (weakness, fatigue, paresthesias, cramps), as compared with 6 of 44 normal subjects (14 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/62\">",
"       62",
"      </a>",
"      ]. However, in another study of more than 2000 elderly individuals, functional mobility (gait speed and walking endurance) was better in those with mild elevations in TSH (4.5 to &lt;7.0",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      than in those with TSH values within the normal range (0.4 to &lt;4.5",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subclinical hypothyroidism may also be associated with defects in verbal memory and executive functioning [",
"      <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]. These defects correct with T4 therapy and are thought to reflect abnormal hippocampal function rather than general cognitive slowing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36585?source=see_link\">",
"       \"Neurologic manifestations of hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a population-based study, subclinical hypothyroidism was associated with an increased risk of Alzheimer Disease (AD) in women but not in men [",
"      <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/66\">",
"       66",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36585?source=see_link\">",
"       \"Neurologic manifestations of hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a pilot study, patients with unprovoked deep venous thrombosis were more likely to have subclinical hypothyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study, patients with subclinical hypothyroidism were more likely to have common bile duct stones, thought to be secondary to sphincter of Oddi dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with coexisting iron-deficiency anemia and subclinical hypothyroidism had a greater increase in hemoglobin when given both iron and thyroid hormone replacement compared with those given iron alone [",
"      <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Undetected subclinical hypothyroidism in pregnancy is a risk factor for miscarriage and low birth weight babies, and possibly poor developmental outcome in the offspring. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link&amp;anchor=H57693631#H57693631\">",
"     \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\", section on 'Subclinical hypothyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EFFECTS OF THYROID HORMONE REPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fundamental clinical question regarding patients with subclinical hypothyroidism is whether they should be treated with thyroid hormone (thyroxine, T4,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    ). Based upon the natural history alone, one might argue that treatment should be started to prevent progression to overt hypothyroidism, particularly in patients with serum TSH values &ge;10",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"    The treatment of patients with TSH values between 4.5 and 10",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    remains controversial, as randomized trials have not shown a consistent benefit with treatment. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Candidates for T4 replacement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hypothyroid signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data regarding the relationship between T4 replacement and improvement in hypothyroid symptoms are conflicting, likely due to differences among the patient populations studied, such as age, TSH concentrations, presence of antithyroid antibodies, and history of prior thyroid disease. In some [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/70-72\">",
"     70-72",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/58,73,74\">",
"     58,73,74",
"    </a>",
"    ], trials, T4 replacement resulted in improved hypothyroid symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cognitive function. The benefit appeared to be limited to patients with baseline serum TSH concentration &ge;10",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"    In a meta-analysis of 12 clinical trials (nine trials with TSH concentrations &lt;10 to 15",
"    <span class=\"nowrap\">",
"     mU/L),",
"    </span>",
"    there were no differences in hypothyroid signs or symptoms, quality of life, or adverse effects between the T4 and placebo groups [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent randomized trials (not included in the meta-analysis) evaluating the effects of T4 on hypothyroid symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cognitive function suggest a lack of benefit. In a double blind randomized cross-over trial of 100 patients with serum TSH between 3.7 and 15.8",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    treatment with a fixed dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    0.100 mg daily resulted in an improvement in the proportion of patients reporting fatigue (89 to 79 percent), but no significant improvement in other quality of life measures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/76\">",
"     76",
"    </a>",
"    ]. In this trial, TSH concentrations were below normal in some patients (range 0.01 to 12.1",
"    <span class=\"nowrap\">",
"     mU/L).",
"    </span>",
"   </p>",
"   <p>",
"    Another randomized trial evaluated the effect of T4 versus placebo on cognitive function in 94 patients (&ge;65 years of age) with serum TSH &gt;5.5",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    (median value 6.6",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/77\">",
"     77",
"    </a>",
"    ]. The dose of T4 was adjusted to maintain the serum TSH in the normal range. Cognitive function was assessed with standard measures of cognitive function (ie, mini-mental status examination) and with the Trail Making Test, a more targeted test of executive function. After 12 months, euthyroidism was achieved by 84 percent of subjects receiving T4 replacement. Achieved median TSH concentrations were 3.7 and 5.4",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    in the T4 and placebo groups, respectively, but TSH values were below normal in some T4 treated patients (range 0.2 to 6.9",
"    <span class=\"nowrap\">",
"     mU/L).",
"    </span>",
"    There were no significant changes in any of the measures of cognitive function over time and no difference between the groups at 6 or 12 months.",
"   </p>",
"   <p>",
"    This trial was limited by a high drop-out rate, particularly in the placebo group, and spontaneous normalization of TSH in 50 percent of subjects in the placebo group. Despite these limitations, the results of the meta-analysis and subsequent trials, in which most patients had TSH &lt;10",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    suggest that treatment of subclinical hypothyroidism with T4 does not result in clinically significant improvement in quality of life, depression, and cognitive function.",
"   </p>",
"   <p>",
"    In patients with subclinical hypothyroidism and goiter, T4 treatment may decrease the size of the goiter. As an example, in a study of 13 patients with subclinical hypothyroidism, treatment with T4 was associated with a significant decrease (median 80 percent) in thyroid volume determined by ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22535?source=see_link&amp;anchor=H6#H6\">",
"     \"Thyroid hormone suppressive therapy for thyroid nodules and benign goiter\", section on 'Nontoxic goiter'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although T4 replacement has been shown to improve a number of cardiovascular risk factors and surrogate cardiovascular endpoints in patients with subclinical hypothyroidism, including dyslipidemia, markers of inflammation, vascular smooth muscle proliferation, vascular reactivity, ventricular function, endothelial function, and carotid intima media thickness, data demonstrating its ability to decrease cardiovascular events are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/36,40,42,76,79-85\">",
"     36,40,42,76,79-85",
"    </a>",
"    ]. In an analysis of the United Kingdom General Practitioner Research Database, ischemic heart disease events were less common among those individuals aged 40 to 70 years treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    (68 events in 1634 treated patients [4.2 percent] versus 97 events in 1459 untreated patients [6.6 percent], HR 0.61 [95% CI 0.39-0.95]) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/86\">",
"     86",
"    </a>",
"    ]. However, in individuals over age 70 years there was no benefit of treatment (104 events in 819 treated patients [12.7 percent] versus 88 events in 823 untreated patients [10.7 percent], HR 0.99) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/86\">",
"     86",
"    </a>",
"    ]. The risk of adverse cardiovascular effects associated with overtreatment once thyroxine is administered, particularly in elderly adults, is unknown. Thus, clinical trials are needed to assess whether thyroid hormone replacement reduces CVD outcomes in patients with subclinical hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3046?source=see_link\">",
"     \"Cardiovascular effects of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Serum lipid and apoprotein concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the meta-analysis of 12 clinical trials (nine trials with TSH concentrations &lt;10 or 15",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    described above, seven of the trials analyzed lipid levels after treatment of subclinical hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/75\">",
"     75",
"    </a>",
"    ]. There were no significant effects of T4 replacement on total cholesterol, HDL, LDL, triglycerides, apolipoprotein A and B, or lipoprotein (a).",
"   </p>",
"   <p>",
"    However, in several randomized trials of patients with subclinical hypothyroidism treated with T4 versus placebo, serum total and LDL cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/36,72,76,87-89\">",
"     36,72,76,87-89",
"    </a>",
"    ] and apoprotein B-100 concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/72,76,88\">",
"     72,76,88",
"    </a>",
"    ] decreased significantly, whereas serum HDL cholesterol, triglyceride, and lipoprotein (a) concentrations did not change [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/72,89\">",
"     72,89",
"    </a>",
"    ]. All but one of these trials included patients with serum TSH concentrations &gt;10",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Candidates for T4 replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although virtually all experts recommend treatment of patients with serum TSH concentrations &gt;10",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    the routine treatment of asymptomatic patients with TSH values between 4.5 and 10",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/10,18,90-92\">",
"     10,18,90-92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In view of data linking subclinical hypothyroidism with atherosclerosis and myocardial infarction, and the increased risk of progression to overt hypothyroidism, we suggest treatment of patients with subclinical hypothyroidism and TSH levels greater than 10",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Cardiovascular disease'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Progression to overt hypothyroidism'",
"    </a>",
"    above.) This recommendation is consistent with that of a clinical consensus group (comprised of representatives from the Endocrine Society, American Thyroid Association, and the American Association of Clinical Endocrinologists) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few data to show benefit or harm of T4 treatment in patients with TSH values between 4.5 and 10",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"    The consensus group did not recommend routine treatment for such patients, but recommended monitoring TSH levels every 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/18\">",
"     18",
"    </a>",
"    ]. However, others have recommended treatment for patients with TSH values in this range because unrecognized symptoms may improve, correction of abnormal serum lipid concentrations may be cardioprotective, and there is little risk associated with monitored T4 replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/90-93\">",
"     90-93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest T4 therapy in non-elderly patients with serum TSH values of 4.5 to 10",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    who have symptoms suggestive of hypothyroidism. Patients with high titers of antithyroid peroxidase antibodies, who may rapidly progress to overt hypothyroidism, and patients with goiter may also benefit from early treatment. Some experts suggest that the presence of risk factors for cardiovascular disease is a reason for initiating treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/10\">",
"     10",
"    </a>",
"    ]. Other experts caution that overtreatment with T4 is common, occurring in as many as 41 percent of individuals &ge;65 years of age, and that overtreatment may result in adverse consequences, such as cardiac arrhythmias, especially in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/94\">",
"     94",
"    </a>",
"    ]. Thus, we do not treat elderly patients (over age 70 years) with subclinical hypothyroidism and TSH between 4.5 and 8",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"   </p>",
"   <p>",
"    We suggest initiating T4 replacement in pregnant women with subclinical hypothyroidism (TSH values above trimester-specific normal reference range with normal free T4) and in women with subclinical hypothyroidism who wish to become pregnant or have ovulatory dysfunction and infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/18\">",
"     18",
"    </a>",
"    ]. Because of the changes in thyroid physiology during pregnancy, trimester-specific reference ranges for TSH should be used [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/95\">",
"     95",
"    </a>",
"    ]. During the first trimester of pregnancy, subclinical hypothyroidism is defined as a serum TSH above 2.5 (above 3",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    in the second or third trimester) with a normal free T4 concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link&amp;anchor=H57693666#H57693666\">",
"     \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\", section on 'Candidates for treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link&amp;anchor=H57693645#H57693645\">",
"     \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link&amp;anchor=H1156384#H1156384\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'Trimester-specific reference ranges'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of pregnant women with normal serum TSH levels and positive antithyroid peroxidase antibodies is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'Thyroid peroxidase antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anecdotal reports suggest that T4 therapy may be beneficial in patients with symptoms of hypothyroidism but normal thyroid function tests. However, in a randomized, crossover trial of 22 such patients, T4 was no more effective than placebo in increasing cognitive function and psychological well-being [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, T4 should",
"    <strong>",
"     not",
"    </strong>",
"    be prescribed for patients with hypothyroid symptoms but normal thyroid function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Arguments for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment will prevent progression to overt hypothyroidism, especially in those with serum TSH concentrations greater than 10 to 15",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    and high serum antithyroid peroxidase antibody concentrations. Treatment in patients with lesser elevations in serum TSH concentrations may possibly ameliorate nonspecific symptoms of hypothyroidism, such as fatigue, constipation or depression, and may decrease the size of goiter, if present. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Hypothyroid signs and symptoms'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22535?source=see_link&amp;anchor=H6#H6\">",
"     \"Thyroid hormone suppressive therapy for thyroid nodules and benign goiter\", section on 'Nontoxic goiter'",
"    </a>",
"    .) Treatment may also improve cardiac contractility and serum lipid concentrations in some patients and secondarily reduce the risk of atherosclerosis. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Cardiovascular disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Arguments against treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arguments against T4 treatment include its cost (for both the hormone and for monitoring its efficacy), the lifelong commitment to daily medication in asymptomatic patients, the potential risk of overtreatment and inducing symptoms from excess thyroid hormone, and the possible induction or exacerbation of angina pectoris or cardiac arrhythmia in susceptible patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/97\">",
"     97",
"    </a>",
"    ], especially in view of data from a community survey showing that 41 percent of patients over age 65 taking thyroid hormone replacement had a subnormal serum TSH [",
"    <a class=\"abstract\" href=\"UTD.htm?3/48/3850/abstract/94\">",
"     94",
"    </a>",
"    ]. Although these concerns are not usually sufficient to counterbalance the potential benefits of therapy in younger patients, we do recommend a higher TSH threshold for treating elderly patients, especially since the upper limit of normal for serum TSH may be higher in this age group. If the patient is not treated, regular follow-up is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Goals of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of therapy is to reduce the patient's serum TSH concentration into the normal reference range. Since the mean serum TSH for the general population is around 1.4",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    with 90 percent having serum TSH levels &lt;3.0",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    many experts recommend a therapeutic TSH target of 0.5 to 2.5",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    in young and middle-aged patients. A TSH target of 3 to 5",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    may be appropriate in patients over age 70 years.",
"   </p>",
"   <p>",
"    There are two approaches to initiating T4 therapy. One option is to start with the lowest dose necessary to normalize the serum TSH concentration, typically 25 to 50 mcg daily. This approach will avoid overtreatment and is most appropriate in the elderly or in patients with underlying cardiovascular disease.",
"   </p>",
"   <p>",
"    For younger patients with Hashimoto's thyroiditis who do not have autonomy (eg, a prior history of toxic adenoma or Graves' disease treated with radioiodine) and who have normal negative feedback, an alternative approach is to initiate treatment at slightly below full replacement doses (1.6",
"    <span class=\"nowrap\">",
"     mcg/kg/day).",
"    </span>",
"    This approach obviates the need for periodic dose increases, should there be progressive autoimmune destruction of their gland. Alternatively, younger patients could be started on low dose therapy, as is recommended for older patients. Dose adjustments and long-term monitoring are the same as for the treatment of overt hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of hypothyroidism\", section on 'Standard replacement therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of hypothyroidism\", section on 'Dose and monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=see_link\">",
"       \"Patient information: Hypothyroidism (underactive thyroid) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"       \"Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subclinical hypothyroidism is defined biochemically as a normal serum free thyroxine (T4) concentration in the presence of an elevated serum thyrotropin (TSH) concentration. Subclinical hypothyroidism may occur in the presence or absence of mild symptoms of hypothyroidism. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A substantial proportion of patients with subclinical hypothyroidism eventually develop overt hypothyroidism. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Progression to overt hypothyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subclinical hypothyroidism may be associated with an increased risk of cardiovascular disease (eg, coronary heart disease, heart failure), particularly when the serum TSH concentration is above 10",
"      <span class=\"nowrap\">",
"       mU/L.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cardiovascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with subclinical hypothyroidism and TSH concentrations &ge;10",
"      <span class=\"nowrap\">",
"       mU/L,",
"      </span>",
"      we suggest treatment with thyroid hormone (T4) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For non-elderly patients with TSH concentrations between 4.5 and 10",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      who have symptoms of hypothyroidism, we also suggest treatment with T4 (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment with T4 can also be considered in non-elderly patients with TSH between 4.5 and 10",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      who have high titers of thyroid peroxidase antibodies, which predict progression to overt hypothyroidism, or goiter. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Candidates for T4 replacement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For elderly patients (over age 70 years) with subclinical hypothyroidism and TSH between 4.5 and 8",
"      <span class=\"nowrap\">",
"       mU/L,",
"      </span>",
"      we suggest",
"      <strong>",
"       not",
"      </strong>",
"      treating (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), in view of the uncertain benefits and the potential for both cardiovascular and skeletal morbidity associated with inadvertent overtreatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link\">",
"       \"Subclinical hyperthyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend initiating T4 replacement in women with subclinical hypothyroidism (TSH values &gt;2.5",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      who are pregnant, who wish to become pregnant, or have ovulatory dysfunction and infertility (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Candidates for T4 replacement'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link&amp;anchor=H57693666#H57693666\">",
"       \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\", section on 'Candidates for treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Synthetic thyroxine (T4) is the treatment of choice for correction of hypothyroidism. For elderly patients and those with underlying cardiovascular disease, the initial dose of T4 is typically 25 to 50",
"      <span class=\"nowrap\">",
"       mcg/day.",
"      </span>",
"      This approach will avoid overtreatment. For younger patients without a history of thyroid autonomy, an alternative approach is to initiate treatment at slightly below full replacement doses (1.6",
"      <span class=\"nowrap\">",
"       mcg/kg/day).",
"      </span>",
"      The goal of therapy is to reduce the patient's serum TSH concentration into the lower half of the age-adjusted normal reference range. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Goals of treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of hypothyroidism\", section on 'Standard replacement therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recommendations for routine screening for hypothyroidism are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link&amp;anchor=H8#H8\">",
"       \"Diagnosis of and screening for hypothyroidism\", section on 'Screening'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/1\">",
"      Bemben DA, Hamm RM, Morgan L, et al. Thyroid disease in the elderly. Part 2. Predictability of subclinical hypothyroidism. J Fam Pract 1994; 38:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/2\">",
"      Bell RJ, Rivera-Woll L, Davison SL, et al. Well-being, health-related quality of life and cardiovascular disease risk profile in women with subclinical thyroid disease - a community-based study. Clin Endocrinol (Oxf) 2007; 66:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/3\">",
"      Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/4\">",
"      Bagchi N, Brown TR, Parish RF. Thyroid dysfunction in adults over age 55 years. A study in an urban US community. Arch Intern Med 1990; 150:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/5\">",
"      Kanaya AM, Harris F, Volpato S, et al. Association between thyroid dysfunction and total cholesterol level in an older biracial population: the health, aging and body composition study. Arch Intern Med 2002; 162:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/6\">",
"      Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/7\">",
"      Parle JV, Franklyn JA, Cross KW, et al. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf) 1991; 34:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/8\">",
"      Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/9\">",
"      Szabolcs I, Podoba J, Feldkamp J, et al. Comparative screening for thyroid disorders in old age in areas of iodine deficiency, long-term iodine prophylaxis and abundant iodine intake. Clin Endocrinol (Oxf) 1997; 47:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/10\">",
"      Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008; 29:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/11\">",
"      Cooper DS, Biondi B. Subclinical thyroid disease. Lancet 2012; 379:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/12\">",
"      Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 2007; 92:4575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/13\">",
"      Despr&eacute;s N, Grant AM. Antibody interference in thyroid assays: a potential for clinical misinformation. Clin Chem 1998; 44:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/14\">",
"      Rix M, Laurberg P, Porzig C, Kristensen SR. Elevated thyroid-stimulating hormone level in a euthyroid neonate caused by macro thyrotropin-IgG complex. Acta Paediatr 2011; 100:e135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/15\">",
"      Loh TP, Kao SL, Halsall DJ, et al. Macro-thyrotropin: a case report and review of literature. J Clin Endocrinol Metab 2012; 97:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/16\">",
"      Sakai H, Fukuda G, Suzuki N, et al. Falsely elevated thyroid-stimulating hormone (TSH) level due to macro-TSH. Endocr J 2009; 56:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/17\">",
"      Gurnell M, Halsall DJ, Chatterjee VK. What should be done when thyroid function tests do not make sense? Clin Endocrinol (Oxf) 2011; 74:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/18\">",
"      Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/19\">",
"      Huber G, Staub JJ, Meier C, et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab 2002; 87:3221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/20\">",
"      Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/21\">",
"      Kabadi UM. 'Subclinical hypothyroidism'. Natural course of the syndrome during a prolonged follow-up study. Arch Intern Med 1993; 153:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/22\">",
"      Rosenthal MJ, Hunt WC, Garry PJ, Goodwin JS. Thyroid failure in the elderly. Microsomal antibodies as discriminant for therapy. JAMA 1987; 258:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/23\">",
"      D&iacute;ez JJ, Iglesias P. Spontaneous subclinical hypothyroidism in patients older than 55 years: an analysis of natural course and risk factors for the development of overt thyroid failure. J Clin Endocrinol Metab 2004; 89:4890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/24\">",
"      D&iacute;ez JJ, Iglesias P, Burman KD. Spontaneous normalization of thyrotropin concentrations in patients with subclinical hypothyroidism. J Clin Endocrinol Metab 2005; 90:4124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/25\">",
"      Meyerovitch J, Rotman-Pikielny P, Sherf M, et al. Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch Intern Med 2007; 167:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/26\">",
"      Hak AE, Pols HA, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000; 132:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/27\">",
"      Lindeman RD, Romero LJ, Schade DS, et al. Impact of subclinical hypothyroidism on serum total homocysteine concentrations, the prevalence of coronary heart disease (CHD), and CHD risk factors in the New Mexico Elder Health Survey. Thyroid 2003; 13:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/28\">",
"      Imaizumi M, Akahoshi M, Ichimaru S, et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 2004; 89:3365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/29\">",
"      Walsh JP, Bremner AP, Bulsara MK, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 2005; 165:2467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/30\">",
"      Razvi S, Weaver JU, Vanderpump MP, Pearce SH. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. J Clin Endocrinol Metab 2010; 95:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/31\">",
"      Rodondi N, Newman AB, Vittinghoff E, et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med 2005; 165:2460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/32\">",
"      Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006; 295:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/33\">",
"      Hyland KA, Arnold AM, Lee JS, Cappola AR. Persistent subclinical hypothyroidism and cardiovascular risk in the elderly: the cardiovascular health study. J Clin Endocrinol Metab 2013; 98:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/34\">",
"      Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010; 304:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/35\">",
"      Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 2012; 126:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/36\">",
"      Monzani F, Caraccio N, Koz&agrave;kow&agrave; M, et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo- controlled study. J Clin Endocrinol Metab 2004; 89:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/37\">",
"      Nagasaki T, Inaba M, Kumeda Y, et al. Increased pulse wave velocity in subclinical hypothyroidism. J Clin Endocrinol Metab 2006; 91:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/38\">",
"      Kvetny J, Heldgaard PE, Bladbjerg EM, Gram J. Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol (Oxf) 2004; 61:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/39\">",
"      Cikim AS, Oflaz H, Ozbey N, et al. Evaluation of endothelial function in subclinical hypothyroidism and subclinical hyperthyroidism. Thyroid 2004; 14:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/40\">",
"      Owen PJ, Rajiv C, Vinereanu D, et al. Subclinical hypothyroidism, arterial stiffness, and myocardial reserve. J Clin Endocrinol Metab 2006; 91:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/41\">",
"      Choi SH, Lee YJ, Park YJ, et al. Retinol binding protein-4 elevation is associated with serum thyroid-stimulating hormone level independently of obesity in elderly subjects with normal glucose tolerance. J Clin Endocrinol Metab 2008; 93:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/42\">",
"      Biondi B, Fazio S, Palmieri EA, et al. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab 1999; 84:2064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/43\">",
"      Iqbal A, Schirmer H, Lunde P, et al. Thyroid stimulating hormone and left ventricular function. J Clin Endocrinol Metab 2007; 92:3504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/44\">",
"      Iervasi G, Molinaro S, Landi P, et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 2007; 167:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/45\">",
"      McQuade C, Skugor M, Brennan DM, et al. Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study. Thyroid 2011; 21:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/46\">",
"      Tseng FY, Lin WY, Lin CC, et al. Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. J Am Coll Cardiol 2012; 60:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/47\">",
"      Gussekloo J, van Exel E, de Craen AJ, et al. Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004; 292:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/48\">",
"      Atzmon G, Barzilai N, Surks MI, Gabriely I. Genetic predisposition to elevated serum thyrotropin is associated with exceptional longevity. J Clin Endocrinol Metab 2009; 94:4768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/49\">",
"      Waring AC, Harrison S, Samuels MH, et al. Thyroid function and mortality in older men: a prospective study. J Clin Endocrinol Metab 2012; 97:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/50\">",
"      Waring AC, Arnold AM, Newman AB, et al. Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study. J Clin Endocrinol Metab 2012; 97:3944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/51\">",
"      Chung GE, Kim D, Kim W, et al. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol 2012; 57:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/52\">",
"      Baldini IM, Vita A, Mauri MC, et al. Psychopathological and cognitive features in subclinical hypothyroidism. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/53\">",
"      Monzani F, Del Guerra P, Caraccio N, et al. Subclinical hypothyroidism: neurobehavioral features and beneficial effect of L-thyroxine treatment. Clin Investig 1993; 71:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/54\">",
"      Haggerty JJ Jr, Stern RA, Mason GA, et al. Subclinical hypothyroidism: a modifiable risk factor for depression? Am J Psychiatry 1993; 150:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/55\">",
"      Tappy L, Randin JP, Schwed P, et al. Prevalence of thyroid disorders in psychogeriatric inpatients. A possible relationship of hypothyroidism with neurotic depression but not with dementia. J Am Geriatr Soc 1987; 35:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/56\">",
"      Engum A, Bj&oslash;ro T, Mykletun A, Dahl AA. An association between depression, anxiety and thyroid function--a clinical fact or an artefact? Acta Psychiatr Scand 2002; 106:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/57\">",
"      Roberts LM, Pattison H, Roalfe A, et al. Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann Intern Med 2006; 145:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/58\">",
"      Jorde R, Waterloo K, Storhaug H, et al. Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment. J Clin Endocrinol Metab 2006; 91:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/59\">",
"      Knudsen N, Laurberg P, Rasmussen LB, et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 2005; 90:4019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/60\">",
"      Fox CS, Pencina MJ, D'Agostino RB, et al. Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med 2008; 168:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/61\">",
"      Asvold BO, Bj&oslash;ro T, Vatten LJ. Association of serum TSH with high body mass differs between smokers and never-smokers. J Clin Endocrinol Metab 2009; 94:5023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/62\">",
"      Monzani F, Caraccio N, Del Guerra P, et al. Neuromuscular symptoms and dysfunction in subclinical hypothyroid patients: beneficial effect of L-T4 replacement therapy. Clin Endocrinol (Oxf) 1999; 51:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/63\">",
"      Simonsick EM, Newman AB, Ferrucci L, et al. Subclinical hypothyroidism and functional mobility in older adults. Arch Intern Med 2009; 169:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/64\">",
"      Samuels MH, Schuff KG, Carlson NE, et al. Health status, mood, and cognition in experimentally induced subclinical hypothyroidism. J Clin Endocrinol Metab 2007; 92:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/65\">",
"      Correia N, Mullally S, Cooke G, et al. Evidence for a specific defect in hippocampal memory in overt and subclinical hypothyroidism. J Clin Endocrinol Metab 2009; 94:3789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/66\">",
"      Tan ZS, Beiser A, Vasan RS, et al. Thyroid function and the risk of Alzheimer disease: the Framingham Study. Arch Intern Med 2008; 168:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/67\">",
"      Squizzato A, Romualdi E, Piantanida E, et al. Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study. Thromb Haemost 2007; 97:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/68\">",
"      Laukkarinen J, Kiudelis G, Lempinen M, et al. Increased prevalence of subclinical hypothyroidism in common bile duct stone patients. J Clin Endocrinol Metab 2007; 92:4260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/69\">",
"      Cinemre H, Bilir C, Gokosmanoglu F, Bahcebasi T. Hematologic effects of levothyroxine in iron-deficient subclinical hypothyroid patients: a randomized, double-blind, controlled study. J Clin Endocrinol Metab 2009; 94:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/70\">",
"      Cooper DS, Halpern R, Wood LC, et al. L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Ann Intern Med 1984; 101:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/71\">",
"      Jaeschke R, Guyatt G, Gerstein H, et al. Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med 1996; 11:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/72\">",
"      Meier C, Staub JJ, Roth CB, et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001; 86:4860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/73\">",
"      Nystr&ouml;m E, Caidahl K, Fager G, et al. A double-blind cross-over 12-month study of L-thyroxine treatment of women with 'subclinical' hypothyroidism. Clin Endocrinol (Oxf) 1988; 29:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/74\">",
"      Kong WM, Sheikh MH, Lumb PJ, et al. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. Am J Med 2002; 112:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/75\">",
"      Villar HC, Saconato H, Valente O, Atallah AN. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst Rev 2007; :CD003419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/76\">",
"      Razvi S, Ingoe L, Keeka G, et al. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab 2007; 92:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/77\">",
"      Parle J, Roberts L, Wilson S, et al. A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study. J Clin Endocrinol Metab 2010; 95:3623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/78\">",
"      Romaldini JH, Biancalana MM, Figueiredo DI, et al. Effect of L-thyroxine administration on antithyroid antibody levels, lipid profile, and thyroid volume in patients with Hashimoto's thyroiditis. Thyroid 1996; 6:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/79\">",
"      Adrees M, Gibney J, El-Saeity N, Boran G. Effects of 18 months of L-T4 replacement in women with subclinical hypothyroidism. Clin Endocrinol (Oxf) 2009; 71:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/80\">",
"      Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 2003; 88:3731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/81\">",
"      Ozcan O, Cakir E, Yaman H, et al. The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf) 2005; 63:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/82\">",
"      Milionis HJ, Tambaki AP, Kanioglou CN, et al. Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect. Thyroid 2005; 15:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/83\">",
"      Turhan S, Tulunay C, Ozduman Cin M, et al. Effects of thyroxine therapy on right ventricular systolic and diastolic function in patients with subclinical hypothyroidism: a study by pulsed wave tissue Doppler imaging. J Clin Endocrinol Metab 2006; 91:3490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/84\">",
"      Faber J, Petersen L, Wiinberg N, et al. Hemodynamic changes after levothyroxine treatment in subclinical hypothyroidism. Thyroid 2002; 12:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/85\">",
"      Shakoor SK, Aldibbiat A, Ingoe LE, et al. Endothelial progenitor cells in subclinical hypothyroidism: the effect of thyroid hormone replacement therapy. J Clin Endocrinol Metab 2010; 95:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/86\">",
"      Razvi S, Weaver JU, Butler TJ, Pearce SH. Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. Arch Intern Med 2012; 172:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/87\">",
"      Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab 2002; 87:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/88\">",
"      Iqbal A, Jorde R, Figenschau Y. Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Troms&oslash; Study. J Intern Med 2006; 260:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/89\">",
"      Mikhail GS, Alshammari SM, Alenezi MY, et al. Increased atherogenic low-density lipoprotein cholesterol in untreated subclinical hypothyroidism. Endocr Pract 2008; 14:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/90\">",
"      McDermott MT, Ridgway EC. Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab 2001; 86:4585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/91\">",
"      Cooper DS. Clinical practice. Subclinical hypothyroidism. N Engl J Med 2001; 345:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/92\">",
"      Gharib H, Tuttle RM, Baskin HJ, et al. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab 2005; 90:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/93\">",
"      McDermott MT. In the clinic. Hypothyroidism. Ann Intern Med 2009; 151:ITC61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/94\">",
"      Somwaru LL, Arnold AM, Joshi N, et al. High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. J Clin Endocrinol Metab 2009; 94:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/95\">",
"      Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011; 21:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/96\">",
"      Pollock MA, Sturrock A, Marshall K, et al. Thyroxine treatment in patients with symptoms of hypothyroidism but thyroid function tests within the reference range: randomised double blind placebo controlled crossover trial. BMJ 2001; 323:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/48/3850/abstract/97\">",
"      Chu JW, Crapo LM. The treatment of subclinical hypothyroidism is seldom necessary. J Clin Endocrinol Metab 2001; 86:4591.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7883 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-201.248.109.99-0CE1CD4C1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_48_3850=[""].join("\n");
var outline_f3_48_3850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CONSEQUENCES OF SUBCLINICAL HYPOTHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Progression to overt hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H415078\">",
"      Non-alcoholic fatty liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neuropsychiatric symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Potential consequences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EFFECTS OF THYROID HORMONE REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hypothyroid signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Serum lipid and apoprotein concentrations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Candidates for T4 replacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Arguments for treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Arguments against treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Goals of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7883\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7883|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/62/37867\" title=\"table 1\">",
"      Causes subclin hypothyroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/19/21820\" title=\"table 2\">",
"      Drugs and thyroid function",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3046?source=related_link\">",
"      Cardiovascular effects of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=related_link\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3418?source=related_link\">",
"      Etiology and natural history of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=related_link\">",
"      Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=related_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28550?source=related_link\">",
"      Lipid abnormalities in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36585?source=related_link\">",
"      Neurologic manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=related_link\">",
"      Overview of thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1626?source=related_link\">",
"      Reduced sensitivity to thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16518?source=related_link\">",
"      Resistance to thyrotropin and thyrotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=related_link\">",
"      Thyroid function in nonthyroidal illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22535?source=related_link\">",
"      Thyroid hormone suppressive therapy for thyroid nodules and benign goiter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/20/327?source=related_link\">",
"      Thyrotropin (TSH)-secreting pituitary adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_48_3851="Dx criteria KD";
var content_f3_48_3851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for Kawasaki disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        The diagnosis of Kawasaki disease requires the presence of",
"fever lasting at least five days without any other explanation combined",
"with at least four of the five following criteria:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bilateral bulbar conjunctival injection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Oral mucous membrane changes, including injected or fissured lips, injected pharynx, or strawberry tongue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Peripheral",
"extremity changes, including erythema of palms or soles, edema of hands",
"or feet (acute phase), and periungual desquamation (convalescent phase)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Polymorphous rash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cervical lymphadenopathy (at least one lymph node &gt;1.5 cm in diameter)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_48_3851=[""].join("\n");
var outline_f3_48_3851=null;
var title_f3_48_3852="Postexposure eval HCW VZV";
var content_f3_48_3852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of health care workers following exposure to varicella-zoster",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Confirm source has varicella-zoster infection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Confirm exposure (ie, confined air space, exposed person not wearing respiratory protection).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        3.",
"Obtain a history of varicella or zoster in the employee. Employee",
"considered immune with a history of infection and may return to work.",
"If employee has a negative",
"or uncertain history, algorithm differs depending on whether or not",
"they have received varicella vaccine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4.",
"        <strong>",
"         Negative or uncertain history and no vaccination",
"        </strong>",
"        - Obtain serologic test. If&nbsp;serology positive, employee may return to work. If serology negative or",
"indeterminate, employee should be furloughed from the health care",
"institution from days 8 through 21 post-exposure and considered for",
"VZIG. VZIG prolongs incubation by one week; therefore, employees who",
"are administered VZIG should be furloughed from days 8 through 28 post-exposure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        5.",
"        <strong>",
"         Negative or uncertain history and history of vaccination",
"        </strong>",
"        - Obtain serologic test. If serology positive, employee may return to work. If serology negative",
"or indeterminate, test should be repeated 5-6 days post-exposure. If",
"second serology positive, employee may return to work. If second",
"serology negative:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        a.",
"        <strong>",
"         Option 1",
"        </strong>",
"        - Furlough during the incubation period (days 8 through 21).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        b.",
"        <strong>",
"         Option 2",
"        </strong>",
"        - Allow to continue working and assess daily for the development of clinical varicella.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Choice of option 2 more likely if exposure was to",
"herpes zoster rather than primary varicella or if exposure did not",
"involve face-to-face contact.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from the UNC Hospitals' Infection Control Policy Manual.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_48_3852=[""].join("\n");
var outline_f3_48_3852=null;
var title_f3_48_3853="Diseases assoc with cryos II";
var content_f3_48_3853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of cryoglobulinemia and their clinical associations (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Autoimmune (continued)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Dermatological disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cold-induced urticaria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cutaneous vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epidermolysis bullosa acquisita",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythema elevatum diutinum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythema multiforme",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pemphigus vulgaris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pyoderma gangrenosum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Inflammatory bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Celiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Crohn's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ulcerative colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Paraneoplastic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrial myxoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone marrow transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Lymphoproliferative disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Chronic lymphocytic leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Chronic meylocytic leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hairy cell leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lymphoma: Hodgkin's and non-Hodgkin's",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Plasma cell disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Dysproteinemias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Macroglobulinemia, primary or secondary (eg, Waldenstr&ouml;m's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Multiple myeloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        POEMS syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Angioimmunoblastic lymphadenopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kaposi's sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycosis fungoides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasopharyngeal carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic membranoproliferative glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Iatrogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacille Calmette-Guerin administration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Influenza vaccine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumococcal vaccine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Biliary, La&euml;nnec's, postnecrotic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endomyocardial fibrosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dispenzieri, A, Gorevic, PD. Cryoglobulinemia. Hematology-Oncology Clinics of North America 1999; 42:2507. Copyright &copy; 1999 W.B. Saunders Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_48_3853=[""].join("\n");
var outline_f3_48_3853=null;
var title_f3_48_3854="Contents: Obstetrics procedures";
var content_f3_48_3854=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Obstetrics procedures",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Obstetrics procedures",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/8/5252\">",
"           Amnioinfusion: Indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/12/43203\">",
"           Amnioinfusion: Technique",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/21/14682\">",
"           Cesarean delivery: Technique",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/43/21176\">",
"           Delivery of the fetus in breech presentation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/11/16570\">",
"           Diagnostic amniocentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/44/37574\">",
"           Neuraxial analgesia and anesthesia for labor and delivery: Options",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/59/38839\">",
"           Evaluation of stillbirth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/31/11768\">",
"           Fetal blood sampling",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/56/40840\">",
"           Gross examination of the placenta",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/49/41752\">",
"           Intrapartum management and outcome of shoulder dystocia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/57/13210\">",
"           Intrauterine fetal transfusion of red blood cells",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/43/29367\">",
"           Peripartum hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/47/34553\">",
"           Prenatal assessment of gestational age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/1/25\">",
"           Prenatal sonographic assessment of fetal weight",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/57/42903\">",
"           Procedure for vacuum assisted operative vaginal delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/31/40439\">",
"           Pudendal and paracervical block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/22/3433\">",
"           Repair of episiotomy and perineal lacerations associated with childbirth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/57/15256\">",
"           Techniques for neonatal circumcision",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/0/41993\">",
"           Techniques for ripening the unfavorable cervix prior to induction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/41/11928\">",
"           The fetal biophysical profile",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/61/36824\">",
"           Ultrasound examination in obstetrics and gynecology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/55/35702\">",
"           Umbilical cord blood acid-base analysis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-2370A7A688-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f3_48_3854=[""].join("\n");
var outline_f3_48_3854=null;
var title_f3_48_3855="Genital herpes";
var content_f3_48_3855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Genital herpes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple grouped vesicles of genital herpes on the shaft of the penis. These lesions are frequently painful.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Larry Millikan. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_48_3855=[""].join("\n");
var outline_f3_48_3855=null;
